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Abstract 
Ex vivo cardiomyocytes production from pluripotent stem cells is highly 
attractive as a future clinical therapy for cardiovascular diseases. Scaled-up 3-
dimensional cell culture can be used to produce clinically relevant cell numbers 
but requires numerous bioprocess design considerations. In this thesis, we 
employed hydrogel encapsulation of mouse embryonic stem cells (mESCs) to 
study various novel design parameters that could be used for large-scale 
cardiomyocyte production. First, we demonstrated that our novel rotary, perfused 
bioreactor provided a dynamic and perfused environment that was superior to a 
commercial rotary wall bioreactor and conventional tissue culture vessels in 
terms of cell numbers and cardiac differentiation. With this novel bioreactor, we 
had also investigated the effects of pH on cardiomyogenesis. Cardiomyogenesis 
was found to be sensitive to different pH values, where slight fluctuations could 
cause significant changes to cell proliferation and cardiac differentiation. Last but 
not least, we utilised ultrasound as a novel mechanical stimulus for cardiac 
differentiation of mESCs and demonstrated its benefits in improving 
cardiomyocyte yield.   
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Summary 
Cardiovascular disease is a leading cause of mortality globally with very limited 
resources for those requiring a heart transplant or suffering severe damages from 
myocardial infarct. Ex vivo generation of cardiomyocytes for cell replacement 
therapy is therefore an appealing opportunity for cardiac diseases. However, the 
ability to produce functional cardiomyocytes with clinically relevant numbers 
faces challenges and requires development of scalable processes and 3-
dimensional (3D) cell cultures. This thesis aims to address key bioprocess 
considerations in for differentiating 3D cultures of pluripotent cells towards 
cardiomyocytes by using murine embryonic stem cells (mESCs) as a cell model 
and employing the strategy of hydrogel encapsulation. 
First, design of the culture platform was considered since different bioreactor 
designs and feeding strategies will result in different hydrodynamic profiles, 
which impact availability of nutrients in the immediate macro- and micro-
environment, thus affecting cardiomyogenesis. In this thesis, a novel rotary 
perfused bioreactor was used to determine how the different culture environments 
might impact cardiac differentiation of encapsulated mESCs. As a comparison, 
mESCs were also differentiated in the conventional tissue culture flasks and the 
commercial high-aspect rotary vessel (HARV) bioreactor. Higher cell numbers 
and viabilities were observed in the dynamic cultures (HARV and novel 
bioreactor) than the static flask cultures, showing the significance of uniform 
environment in 3D cultures of cells. Meanwhile, improved cardiomyogenesis was 
observed by earlier and higher expressions of cardiac genes such as myosin 
heavy chains and cardiac troponin T in the novel bioreactor’s perfused 
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environment. From this study, it was shown that the novel bioreactor provided a 
dynamic and perfused environment that was favourable for cardiomyogenesis and 
shown to be conducive for producing cardiomyocytes with clinically relevant 
numbers.  
Differentiation of ESCs appears to be rather sensitive to pH. Literature has shown 
that pH affected contractile properties of cardiomyocytes and stem cell fate. 
When encapsulated mESCs were cultured under different pH environment, lower 
proliferation and viability was observed at pH 6.8 than at pH 7.1 and 7.4. 
Meanwhile, a lower extent of cardiomyocyte differentiation and higher residual 
pluripotency occurred at pH 6.8. These showed the high sensitivity of mESCs in 
cardiac differentiation towards pH environment, where a slight pH fluctuation 
can cause drastic changes. Therefore, it is important to maintain a tight control on 
environmental parameters so as to ensure high cell yields and quality in a scaled-
up production involving pluripotent stem cells.  
To improve the yield and contractile properties of cardiomyocytes derived from 
cell sources, mechanical stimulation was incorporated. In the last chapter of this 
thesis, a novel application of ultrasound on cardiomyocyte differentiation from 
mESCs was studied. Low intensity ultrasound was found to enhance 
cardiomyocyte differentiation of mESCs greatly in both conventional 2D 
differentiation and 3D encapsulated cultures. Besides increasing cardiomyocyte 
yield, spontaneous endodermal differentiation was also inhibited by ultrasound. 
This translated to an increase in mesodermal selectivity during mESC 
differentiation, hence improving cardiomyocyte yield and purity. These findings 
strongly suggest the feasibility of using a novel application of ultrasound for 
improving cardiac differentiation from pluripotent cell sources. 
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In the effort to develop a scalable 3D bioprocess for generating cardiomyocytes, 
this thesis addressed three important aspects in an indefinite list of factors: (1) 
cell culture platforms, (2) pH environment, and (3) incorporation of a mechanical 
stimulus (i.e. ultrasound). These studied areas have shown their impact on 
cardiomyogenesis of mESCs and could be used as references to study and design 
an optimal bioprocess to produce cardiomyocytes of clinically relevant numbers 
and contractile properties from human pluripotent stem cells. 
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Cardiovascular disease (CVD) is a leading cause of mortality in most developed 
countries and accounted for 30% of all deaths worldwide in 2008 [1]. Moreover, 
increased affluence and lifestyle habits in these developed countries will only 
aggravate current situation. For instance, current statistics of people suffering 
from obesity and having lack of healthy lifestyle in the United States predicted an 
increase in the number of people suffering from heart diseases and also an 
increased associated healthcare costs [2]. Among the mortality rates caused by 
CVDs, coronary heart disease was responsible for 42% of this population. In 
patients suffering from coronary heart disease, blood vessels become constricted 
due to causes such as fatty deposit. This limits blood supply to the heart and 
eventually causes myocardial ischemia. During myocardial ischemia, limited 
oxygen and nutrient supply to cardiac muscle cells results in cell death, causing 
infarction. The infarcted area then undergoes inflammation and forms 
collagenous scar tissue, which is void of cardiac muscle functionality such as 
muscle contraction and electrical conduction. This will result in decreased cardiac 
ventricular working capacity and increases the risk of heart failure. Till date, 
clinical interventions have yet to restore full functionality in the infarcted area. 
Patients who suffer from severe heart damage have to undergo heart 
transplantation for regaining full cardiac function. However, availability of 
suitable heart donors is very scarce. Therefore, there is a need to seek other 
clinical therapies which can allow patients to regain cardiac functionality and are 
relatively more accessible for the expanding number of patients.  
Given the current advances in biotechnology and stem cell research, a promising 
therapy for cardiac regeneration is to obtain cellular products through cardiac 
tissue engineering for repairing the infarcted heart muscles. However, several 
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major challenges remain in the roadmap of using cardiac tissue engineering for 
CVD therapies. These challenges include generation of cellular products with 
clinically relevant cell numbers, cardiac properties and tissue integration. 
Therapeutic applications require a local administration of 108 – 109 of functional 
cardiomyocytes per treatment in order to replace the damaged ventricular 
cardiomyocytes in a post-infarct patient [3]. Conventional two-dimensional (2D) 
methods using tissue culture polystyrene (TCP) has been extensively used for 
producing cardiomyocytes but can be impractical and laborious for large-scale 
production. Moreover, cells cultured on TCP face high possibility of altered 
morphologies because of the adherence to hard surfaces. Such altered 
morphologies will result in unnatural cell behaviours that differ significantly 
from the three-dimensional (3D) in vivo environment. 3D culture systems have 
been developed to mimic the physical and structural components of the in vivo 
microenvironment, facilitating 3D cell-cell and cell-matrix interactions. 
Therefore, in cardiac tissue engineering, the goal is to design 3D environments 
that would bear greater resemblance to cardiomyocytes in the myocardium than 
2D cultures [4, 5]. 
One major challenge in obtaining cellular products for clinical therapies is to 
obtain clinically relevant cell numbers readily. To achieve this, scalable platforms 
are usually needed and one of such platform is the bioreactors. Utility of 
bioreactors can also reduce inter-batch variability through uniform mixing and 
control and monitoring of culture parameters. Several studies have demonstrated 
the ability of bioreactor cultures to produce cardiomyocytes in numbers of 108 
magnitude [6, 7]. During the development to obtain suitable bioreactor designs, 
different design parameters should first be considered. Hydrodynamics is an 
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important design factor that will affect cell fate through availability and 
distribution of soluble cues and physical stress in the culture environment.  
Aside from the need to achieve clinically relevant cell numbers, the quality of 
differentiated cardiomyocytes must be ensured to be suitable for transplantation, 
i.e. high purity and ability to perform contractile function. Therefore, it will be 
necessary to maximise the yield of cardiomyocytes. Besides using chemical 
agents to enhance cardiomyogenesis, another approach is to utilise mechanical 
stimulation, which has been shown to aid cardiomyocyte differentiation by  
increasing cardiomyocytes numbers and improving contractile functions [8-10]. 
Mechanical stimulation can also be incorporated into the bioreactor design and 
this would provide an integrative approach. 
1.1 Hypothesis and objectives 
In the pursuit of developing a better cell culture platform for 3D cardiac tissue 
engineering from pluripotent cells, this thesis seeks to define parameters that 
would affect an optimal design of the bioprocess. Control of extracellular 
microenvironment is hypothesised to direct cell fate decisions; different design 
parameters that influence hydrodynamics, nutrient transport and even mechanical 
stimuli would affect yield and purity of cardiomyocytes from pluripotent cell 
sources. Such parameters includes, but are not limited to, the hydrodynamic flow 
within a culture vessel, the environmental pH and any physical stimulation on the 
cells.  
This thesis aims to investigate how the three stated parameters can affect 
cardiomyogenesis from pluripotent embryonic stem cells. As these works 
involved a large-scaled cell culture environment and due to the ethical 
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considerations of using human embryonic stem cells, murine embryonic stem 
cells (mESCs) was adopted as a model to demonstrate the impact of various 
bioprocess parameters on cardiomyogenesis of pluripotent stem cells. mESCs had 
been extensively studied and were established in methods of clonegenity, ex vivo 
expansion and differentiation.  However, for clinical applications, human ESCs 
(hESCs) or human induced pluripotent stem cells (IPSCs) should be used. 
Though mESCs and hESCs are both derived from the inner cell mass tissue of 
embryos, share the key pluripotent transcription factors (Oct-4, Nanog, Sox-2) 
and can differentiate to somatic cell lineages, they displayed fundamental 
species-specific differences in their in vitro growth characteristics and self-
renewal signalling pathways [11, 12]. Human ESCs were found to share several 
defining features with the less-pluripotent murine epiblast stem cells (EpiSCs), 
emphasizing that conventional culture conditions may have yet been optimised to 
stabilise and propagate hESCs [13, 14]. Hanna et al. had successfully rewired 
hESC and human IPSCs to a more immature state, which was beneficial to 
clonogencity and ex vivo differentiation efficiency [14]. While more studies are 
being conducted to establish hESC model and to optimise its culture conditions, 
mESC was used as a more cost-efficient model to generate hypotheses on how 
the investigated bioprocess parameters will affect a large-scaled cardiac 
differentiation of human pluripotent cells. 
In the next section (Chapter 2), different types of cells which can be used as 
sources for obtaining cardiomyocytes were reviewed. Selected bioreactor designs 
which are currently available and their nutrient transport considerations were also 
briefly discussed, and were followed by a brief overview on the usage of 3D 
substrates and physical stimulation for cardiomyogenesis. In Chapter 3, a novel 
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bioreactor, which incorporated rotary mixing and perfusion, was utilised to 
differentiate mESCs towards cardiomyocytes and its efficacy was compared to 
those of conventional TCP cultures and commercial rotary wall bioreactor, 
HARV. Thereafter sensitivity of ESC differentiation towards culture 
environmental parameters, specifically extracellular pH, was studied in Chapter 
4. Through this, the importance of a bioprocess’s ability to ensure uniformity and 
consistency in the cell culture environment would be demonstrated. Last but not 
least, the feasibility of using ultrasound to complement cardiomyogenesis was 
investigated to show its ability as mechanical stimuli in cardiac tissue 
engineering. Though ultrasound had been used for bone and cartilage 
regeneration, it has not been studied for cardiac regeneration. The effects of 
ultrasound on cardiomyogenesis of mESCs were reported for the first time in 
Chapter 5.  
To apply tissue engineering and regenerative medicine for clinical therapies, 
much work is required to determine efficacy and safety of a stem cell product. 
The last chapter in this thesis would discuss the significance of the works 
presented in this thesis and the future developments that are required for 
translating these works to clinical applications.  
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2.1 Cell sources for obtaining cardiomyocytes 
Cardiomyocytes are terminal somatic cells and have limited proliferative 
capacity. Therefore, it is challenging to use cardiomyocytes to produce large cell 
numbers required for cardiac construct despite their functional utility. This means 
that there is a need to consider cell types with higher proliferative ability as 
sources to obtain cardiomyocytes for transplantation. Numerous studies have 
differentiated various cell types into cardiomyocytes in vitro, one such cell type is 
the adult skeletal myoblasts. Myoblasts, being precursors of myocytes, have 
higher proliferative capacities than cardiomyocytes and still contain contractile 
apparatus [15]. Since they can be extracted from patient’s own tissue, it will 
allow autologous transplantation too. However, as myoblasts are from the 
skeletal muscle lineage, their integration into the myocardium environment 
results in problems like arrhythmias and fibrosis [16, 17]. 
Another potential source is progenitor cells from the cardiac lineage such as 
cardiac progenitor cells (CPCs) and cardiac stem cells (CSCs) [18, 19]. These 
cells appear promising as sources for cardiac regeneration due to their high 
cardiogenic lineage specificity and high self-renewal ability as immature 
progenitors [20-22]. However, studies suggested that their ability to cause cardiac 
regeneration might not be due to directed cardiomyogenesis of these transplanted 
progenitors but due to indirect mechanisms inducing endogenous regeneration of 
the host’s myocardium [23] or residual myocardial tissue fragments from the 
isolation process [24]. Therefore, more studies are still required to determine their 
suitability. Moreover, isolation of CPCs and CSCs involves a complex process, 
posing limitations to obtain sufficient numbers readily for the production of 
cardiomyocytes.  
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Mesenchymal stem cells (MSCs) are adult stem cells, which are extensively 
studied for many tissue engineering applications.  Common sources of MSCs 
include bone marrow and umbilical cord. MSCs from bone marrow (BM-MSCs) 
and umbilical cord (UC-MSCs) have demonstrated abilities to differentiate into 
adiopogenic, osteogenic, chondrogenic and cardiomyogenic lineages [25-27]. 
BM-MSCs have a distinct advantage of being able to inhibit inflammation and 
evade immune detection [28-31]. This can then prevent rejection and improve 
recovery during transplantation. However, extraction of BM-MSCs is highly 
invasive and painful, making it difficult to obtain sufficient numbers from donors. 
On the other hand, extraction of UC-MSCs is from the placenta or cord lining and 
thus is non-invasive. Despite the potential in using MSCs for cardiomyogenesis 
and its demonstrated safety and clinical benefits, both human and non-human 
MSCs have not produced significant yields of cardiomyocytes with contractile 
abilities [32-37]. Therefore, more studies are necessary to qualify the potential 
clinical benefit of MSCs for cardiac diseases. 
The discovery of embryonic stem cells (ESCs) presents a highly proliferative and 
pluripotent cell source that seems promising to generate high cell numbers of all 
lineages. ESCs can spontaneously differentiate into cardiomyocytes in vitro [38]. 
An advantage of using ESCs is their equal differentiation potential towards 
cardiogenesis and vasculogenesis. This can be highly beneficial to regenerate a 
myocardium with vascular network [39, 40]. However, ESCs can also 
spontaneously differentiate into other undesired cell lineages, leading to teratoma 
formation. In overcoming this problem, cardiogenic cells can first be separated 
from other differentiated cells, thus increasing the purity of cardiomyocytes and 
vascular cells prior to transplantation [41, 42]. Nevertheless, utility of ESCs in 
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clinical application still raises issues in non-autologous transplantation, immune 
rejection, fibrosis, arrhythmia [43]  and ethical concerns. 
One discovery that arose as means to resolve the ethical concerns of using 
embryos to obtain ESCs is the induced pluripotent stem cells (IPSCs). 
Cardiomyogenesis of murine IPSCs was first reported in 2008 [44-46]. 
Subsequently, human IPSC-derived cardiomyocytes were also obtained and 
found to be similar to those derived from ESCs in their expression of cardiac 
genes and activity in action potentials [47, 48]. Utility of IPSCs also opens up 
possibilities for autologous transplantation. However, obtaining IPSCs from 
somatic cells requires stable transfection, where the most reliable method is viral 
transfection currently. Unfortunately, such viral transfection could lead to 
possible karyotypic abnormalities, undermining its clinical suitability. Non-viral 
transfection methods like transposons [49], protein- and mRNA-based delivery 
[50-52] and small molecules [53]  have been developed but are less efficient. 
Moreover, utility of IPSCs, similar to ESCs, faces the possibility of teratoma 
formation upon transplantation in the presence of any residual pluripotent cells. 
Many cell types can be considered for obtaining cardiomyocytes for regenerative 
clinical therapies. Each different source has their own advantages and limitations, 
as summarised in Table 2.1. In considering the possible cell sources, one must 
determine the desired quantity and quality of the final cell product. This means 
selecting suitable sources with the proliferative and differentiating capacities 
towards clinically relevant numbers, lineage specificity, and maturity of derived 
cardiomyocytes. With a suitable cell source and a systematic approach in 
bioprocess engineering, tissue engineering applications of cardiomyogenesis in 
clinical applications will then be achievable. 
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Table 2-1 Summary of pros and cons of discussed cell sources for obtaining 
cardiomyocytes 
Cell source Pros Cons
Myoblasts Contractile apparatus Integration with host tissue
Autologous transplantation
Cardiac progenitors Lineage specificity Difficult to extract




ESCs High proliferative capacity Teratoma formation
iPSCs High proliferative capacity Teratoma formation
Need for stable and safe 
transfection method
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2.2 Utilising embryonic stem cells for cardiomyogenesis 
2.2.1 Overview of embryonic stem cells 
When an embryo is fertilised, gamete cells of the sperm and those of the embryo 
will join to form an initial cell called the zygote. The zygote next undergoes rapid 
replication and division into 2-, 4-, 8-, 16-cell ovum. Upon reaching 16-cell stage, 
cell compaction will start. A morula is then formed where the outer cells start to 
be more densely packed, forming a cavity and leaving some cells in the interior. 
Further cell expansion will form a blastocyst of 50-150 cells where the outer shell 
of cells is called trophectoderm and the interior cells called inner cell mass 
(ICM). ESCs are derived from the ICMs for ex-vivo uses. This process is briefly 
illustrated in Figure 2.1. 
 
1-cell zygote 2-cell zygote 4-cell zygote 8-cell zygote 
(a) (c) (d) 
(e) (f) (g) 
Morula 
– Start of 
compaction 
Blastocyst 
Inner cell mass (ICM) 
Trophectoderm 
(b) 
Figure 2-1 Development of fertilized embryo to blastocyst 
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ESCs are unique for two distinctive properties: (1) their pluripotency and (2) their 
ability for indefinite symmetrical self-renewal. Being derived from the blastocyst, 
a form of early stage developing embryo, ESCs are pluripotent, i.e. they have the 
ability to differentiate into all somatic cells in the body, as illustrated in Figure 
2.2. This is different from the adult stem cells isolated from developed tissues. 
Adult stem cells are only multipotent, i.e. they have the ability to differentiate 
into cells of limited lineages and not all lineages. Together with ESCs' ability for 
unlimited self-renewal, ESCs' potential in regenerative therapies shows a distinct 






























Figure 2-2 Examples of different somatic cells derived from pluripotent 
embryonic stem cells (Adapted from sigmaaldrich.com) 
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The indefinite self-renewal property of ESCs can be attributed to the fact that 
ESCs do not require external stimulus to initiate DNA replication unlike 
differentiated somatic cells. As seen in cell cycle illustration (Figure 2.3), the G1 
checkpoint is absent and S phase of DNA synthesis forms the bulk of ESCs' 
cycle. To ensure pluripotency during the indefinite self-renewal, assays have 
been developed based on genes or surface antigens associated with 
undifferentiated ESCs [54, 55]. Such markers include stage-specific embryonic 
antigen (SSEA) series, tumour rejection antigen (TRA) series, cluster of 
differentiation 9 (CD9), alkaline phosphatase activity, Nanog, and octamer 
binding factor 3/4 (Oct3/4). 
Oct3/4 has been widely used to identify undifferentiated ESCs. It is expressed 






G0: Gap 0 phase – Resting  
G1: Gap 1 phase – Cell growth 
S: Synthesis phase - DNA replication 
G1: Gap 2 phase – Cell growth 
M: Mitosis phase – Cell division 
 
Figure 2-3 Cell cycle of embryonic stem cells, where synthesis phase is 
longer and gap phases are shorter than most somatic cells 
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[56]. Oct3/4 plays a crucial role in determining and monitoring the cell fate of 
ESCs. For instance, it participates in activation and inhibition of different target 
genes to maintain ESCs in a proliferating and non-differentiating phenotype [57]. 
During gastrulation in vivo, it is down-regulated when ESCs differentiate to 
primitive ectodermal and trophectodermal cells [58]. Niwa et al. has also 
demonstrated the sensitivity of ESCs to expression levels of Oct3/4 [59]. When 
Oct3/4 expression is lower than the critical threshold of two-fold upregulation, 
differentiation into embryonic ectoderm and mesoderm will still occur. 
2.2.2 Differentiation of embryonic stem cells towards cardiomyocytes 
Being a pluripotent cell, ESC can differentiate into cells of all three lineages: (1) 
endodermal lineage, (2) mesodermal lineage, and (3) ectodermal lineage. To 
understand how ESCs can differentiate to cardiomyocytes amongst all cells, in 
vivo embryonic development can be used as a reference. During the blastocyst 
stage, the inner cell mass is surrounded by trophectoderm and primitive 
endoderm (as seen in Figure 2.4). The inner cell mass will start to differentiate to 
primitive ectoderm (epiblast). Meanwhile, the primitive endoderm differentiates 
to parietal and visceral endoderm, which are localised in the anterior region [60]. 
Soon after, primitive ectoderm cells of the epiblast lines over the distal visceral 
endoderm and triggers various signals for gastrulation stage [61]. During 
gastrulation, programmed migration of epiblast cells results in formation of a 
primitive streak along the embryo's posterior axis which will become 
mesendodermal cells [61, 62]. Mesendoderm is the precursor of mesoderm and 
endoderm and since cardiomyocytes are of mesodermal lineage, cardiac 
progenitors will also be formed here [63].  
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In general, there are four main steps in ESC differentiation towards 
cardiomyocytes: (1) commitment towards mesoderm, (2) specification towards 
cardiac progenitors, (3) differentiation towards cardiomyocytes and (4) 
maturation of differentiated cardiomyocytes. As reviewed by Rajala et al. [64], 
different gene expressions can be used to identify different stages of this process. 
During ESC's induction towards mesodermal lineage, transcription factors 
Brachyury-T and Mesp-1 can be used to identify the primitive streak mesodermal 
and cardiogenic mesodermal commitment respectively. Mesp-1 was found to 
promote mesoderm development towards cardiac specificity by binding to 
regulatory DNA sequences of promoters in the cardiac regulatory network and 
also by repressing key genes regulating other mesoderm derivatives [65, 66]. 
(a) Blastocyst (b) Formation of epiblast and 
visceral endoderm 
(c) Lining of epiblast and  
positioning of primitive streak 
(d) Gastrulation 
Figure 2-4 In vivo early post-implantation development of embryo 
(Adapted from Tam and Loebel, 2007 [61]) 
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Nkx2.5 is a cardiac progenitor transcription factor that Mesp-1 targets to promote 
mesodermal specificity towards cardiac lineage. It can also be used to monitor 
ESC specificity towards the cardiac lineage. Last but not least, expressions of 
cardiac signalling or structural proteins can be used to check the extent of ESC 
differentiation to cardiomyocytes. Some examples of these markers are α-actinin, 
myosin heavy chains and cardiac troponin T. Figure 2.5 (as adapted from Cheung 
and Singha, 2011 [67].) briefly illustrates this differentiation pathway. 
 
Figure 2-5 Schematic diagram of ESCs' differentiation pathway towards 
cardiomyocytes and other relevant cells of mesodermal lineage (Adapted 
from Cheung and Singha, 2011 [67])  
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To enhance in vitro cardiomyogenesis of ESCs, numerous studies have 
investigated different soluble factors which were favourable. Soluble factors 
provide biochemical signals which play a key role in influencing cellular 
pathways and cell fate. Transforming growth factors- β (TGF-β) and bone 
morphogenetic proteins (BMPs) are important in regulating early embryogenesis 
such as morphogenesis in embryo and induction of ventral mesoderm [68, 69]. It 
was also reported that these growth factors such as TGF-βs, BMPs and activins 
could increase cardiomyogenesis of both hESCs and mESCs, showing increased 
cardiac expressions and beating areas [70-75]. However, commercial growth 
factors are usually expensive for usage in large scale culture. Cocktails of factors 
produced by cultures of other cell lineages can also have similar benefits on 
cardiomyogenesis of ESCs. One instance is the viseral endoderm-like (END-2) 
cells. Co-culture with these cells or using their conditioned medium can 
contribute to efficient formation of cardiac progenitors from both hESCs and 
mESCs [76-79]. Another possible candidate is the liver cell line. Cultures of liver 
cancer cells (HepG2) were found to produce soluble factors that efficiently 
directed mESCs towards mesodermal lineage [79, 80], which could then increase 
cardiomyocyte differentiation.  
Chemicals are preferred over growth factors due to their economic benefits for 
large scale cultures. Several chemicals have also been observed to promote 
cardiomyogenesis. They include DNA demethylating agents such as 5-aza-2’-
deoxycytidine (decitabine) [81] and 5-azacytidine (azacitidine) [82] which 
increased the cardiac gene expressions of hESCs and mESCs respectively. 
Meanwhile derivatives of vitamin A and vitamin C were also used for cardiac 
differentiation of mESC [83-85]. Cardiogenol C is a small diaminopyrimidine 
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chemical which is a potent inducer of cardiomyogenesis. It was reported to 
increase cardiac myosin heavy chain (MHC) expression in mESCs [86]. It could 
also upregulate Wnt11 expression, which is involved in essential pathways 
regulating cardiac specification [87, 88]. 
Soluble factors have a significant impact on cardiomyogenesis via the 
biochemical cues they provide. However, their efficacy does not depend solely on 
the factor itself, but also on their availability to cellular microenvironment. In 
scaled-up cultures, the availability of nutrients and biochemical factors will be 
heavily influenced by hydrodynamic profiles in the culture vessels. Meanwhile, 
physical cues can also play a key role in determining cell fate of ESCs. Such 
physical cues can come from mechanical or electrical stimulation.  
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2.3 Utilising bioreactors for cardiomyogenesis 
Conventional methods of in vitro cardiomyocyte differentiation from different 
cell sources are conducted in 2D plate cultures, involving the use of TCPs. 
Typically, cardiomyogenesis from these cells involve multi-step procedure. The 
cells first undergo proliferation to reach the required cell numbers and then 
differentiation toward the cardiomyogenic lineage. For instance, ESCs will be 
cultured as an adherent culture on TCP to expand till the required numbers. 
Thereafter, it will be suspended as aggregates to form embryoid bodies (EBs). 
Last but not least, these EBs will be replated on TCP for directed cardiomyocyte 
differentiation. TCP has a low area-volume ratio and restricts the cell densities 
achieved on these 2D platforms. Therefore, expansion to clinically relevant cell 
numbers will require handling large number of TCP plates. Being a multi-step 
procedure, this quantity of TCP plates will usually make such conventional 
differentiation process laborious and susceptible to high inter-batch variability.  
With current biotechnology advances, one can consider various possible 
bioreactor configurations in the scale up of tissue engineering applications to 
meet specific applications and user preferences.   
2.3.1 Bioreactor configurations for cardiomyogenesis 
One commonly studied configuration is the spinner flask system [6, 7, 42, 89]. 
There are currently a few different commercially available configurations such as 
the Sartorius 2L Biostat MD and Dasgip cellferm-pro system. A spinner flask 
generally consists of an impeller, as illustrated in Figure 2.6 (a). The impeller 
provides a mixing action, thus ensuring a well-mixed environment for cell 
culture. A well-mixed environment improves homogeneity of the cell population 
during proliferation, EB formation (when ESCs are used), and directed 
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differentiation. During spinner flask cultures, the cells are either suspended as 
substrate-free cellular aggregates or seeded on scaffolds [7, 42]. Advantages of 
this bioreactor design include ease in scale-up and readily available monitoring 
capabilities. However, there are concerns that the fast spinning impeller motion 
produces a high shear stress environment that can cause fatal cell damage and be 
detrimental to cardiomyogenesis. 
 
Another common bioreactor configuration is the microgravity simulated rotating 
systems. The commercial available system is the rotary cell culture systems 
(RCCS) by Synthecon. Such system achieves homogenous mixing without using 
impellers. It was first designed by NASA to investigate the effects of 
microgravity on cells and tissues. Microgravity is simulated via vertical rotation 
of the culture vessel, resulting cells to be suspended in the vessel's central region. 
This rotating motion can also provide homogeneous mixing under an ultra-low 
shear stress environment. RCCS exists in two main configurations: the high-
aspect rotating vessel (HARV, Figure 2.6 (b)) and the slow-turning lateral vessel 
(STLV, Figure 2.6 (c)). These two configurations produce minimal shear stress, 
thus will be suitable platforms for cell cultures requiring a low shear stress 
(c)  
Spinner flask RCCS - HARV RCCS - STLV 
Figure 2-6 Diagrams of some commonly used configurations: 
(a) spinner flask, (b) RCCS - HARV, and (c) RCCS - STLV 
(b)  (a)  
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environment. Cardiomyogenesis studies have also been conducted in RCCS [90-
92], demonstrating that the utility of such systems is feasible.  As environments 
of low shear stress with upper limits of 2.5 dyn/cm2 are typically more favourable 
for cardiomyocyte maturation [8, 93-95], utility of RCCS have a great potential 
to produce clinically relevant cardiomyocyte numbers. 
Apart from the two commercial bioreactor designs above, novel bioreactors have 
been developed by individual research groups for cardiomyogenesis. One distinct 
feature in several bioreactors is the incorporation of pulsatile flow [8, 9, 96-98]. 
Pulsatile flow can introduce mechanical stimulation or shear stress to cardiac 
constructs and enable directed cell differentiation or cardiomyocyte maturation. 
For instance, Hoerstrup et al. designed a bioreactor [96], as seen in Figure 2.7 (a), 
which used airflow ranging from 50 – 2000 ml/min to provide a systemic 
pressure of 10 – 240 mmHg for mechanical stimulation . First, controlled pulsed 
airflow was introduced into the chamber (1), expanding the silicone diaphragm 
(3). This would induce mechanical stimuli on the cellular construct seeded in 
position (5) when the expanded silicone diaphragm pushed the fluid though the 
channel (4) and cellular construct. Brown et al. [8] has also designed a pulsatile 
perfused bioreactor to provide physiological flow rate and shear stress through 
pulsatile fluid flow  (illustrated in Figure 2.7 (b)). Cardiac construct was held in 
position (3) by being sandwiched between gaskets (2) and meshes (1) and was 
subjected to 1Hz pulsatile flow at 0.32 ml/min or 1.50 ml/min. Under these 
pulsatile flows, improved cardiomyocyte maturation was achieved as indicated 
by the low excitation threshold, higher maximum capture rate and contraction 
amplitude.  
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2.3.2 Mass transport within bioreactors 
One main difference between bioreactor cultures and conventional flask cultures 
is the presence of hydrodynamic flow. Hydrodynamics will affect flow patterns 
within a culture vessel and will predicate the transport and availability of 
nutrients and soluble factors to the cells. In conventional flask culture, where the 
environment is a static condition with no hydrodynamic flow, transport of soluble 
factors is mainly via diffusion through the culture medium. Diffusion in static 
conditions is generally slow and will not be able to replenish the consumed 
factors at different localised areas of the cell culture. The lack of fluid flow will 
lead to concentration gradients within the bulk medium and localised extreme 
conditions, posing several control and monitoring challenges for large-scale cell 
production. To minimise non-homogeneous culture environments, improved 
uniformity in the culture vessel can be achieved by convective transport.  
 
 
(a)  (b)  
Figure 2-7 Novel bioreactors incorporating pulsatile fluid flow as 
mechanical stimuli on seeded cells, as designed by  (a) Hoerstrup et al. 
[96], and (b) Brown et al. [8]. 
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2.3.3 Bulk convective transport in bioreactors 
In dynamic bioreactors, bulk fluid transport is facilitated by convection, 
providing a more homogeneous environment within the culture vessel. Under 
such conditions, more efficient transport of soluble factors can be achieved, 
leading to higher cell expansion and viabilities [92, 99]. In this well-mixed 
environment, the peripheral surface of cardiac constructs gave rise to more 
uniformly distributed cardiomyocytes [100]. Apart from higher cell numbers, 
viabilities and uniformity, cardiomyogenesis was also enhanced in well-mixed 
environments. For instance, cardiac genes like Nkx2.5 and α-myosin heavy chain 
gave a 27-fold and 9-fold increase in the horizontal rotary culture as compared to 
the static cultures [90]. Similarly, gene expressions of α-myosin heavy chain and 
atrial natriuretic factor were also higher in differentiating mESCs in rotating wall 
vessels than in static cultures [92]. 
Mixing will introduce different flow patterns inside the vessels, thus different 
methods of mixing will affect the flow patterns and the overall convective 
transport efficacy. Horizontal shaking used by shaker flask system were found to 
produce a lower mass transfer efficacy than spinner flasks [101]. Thus such 
systems may not be suitable for cultures having high oxygen demands, such as 
cardiomyocyte maturation. Agitation speed must also be optimised to be fast 
enough to eliminate concentration gradients but gentle enough to minimise any 
deleterious shear stress. Papadaki et al. has compared constructs of neonatal rat 
cardiomyocytes cultured in RCCS and spinner flasks [100]. They observed that 
though both bioreactor configurations provided homogeneous environments, the 
constructs in RCCS had higher cellularity levels (1.5 fold) and higher expression 
of Connexin-43 (3.5 folds) and creatin kinase-MM (2 folds) than those in spinner 
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flasks. This difference might be attributed to the higher shear stress in spinner 
flasks being detrimental to cardiomyogenesis. Similar to the agitation speed, the 
vertical rotating speed of RCCS must be optimised. The optimal speed should 
achieve microgravity and maintain the cells in the central zone to minimise any 
collision with the wall boundary of the vessel. Consolo et al. have shown that this 
speed is 25 rpm for hydrogel-encapsulated ESCs in HARV bioreactor [92]. 
Meanwhile, a rotation speed of 18 rpm is required for cells seeded in 600 µm 
microbeads and cultured in HARV [102]. 
Though convection can improve homogeneity of bulk fluid tremendously, the key 
solute transport within 3D construct is still molecular diffusion. The efficiencies 
of nutrient transport within constructs affect the cell’s microenvironment and thus 
cell fate such as cardiomyogenesis. Diffusional limitations can cause 
heterogeneous cell distribution, and cells in regions distant from construct 
periphery may experience compromised cell viability due to limited nutrient 
supply. Despite homogeneity in bulk fluid, cardiac constructs in RCCS and 
spinner flasks only had a viable cellular region of up to 100 µm in thickness 
along the peripheral region [103, 104]. Meanwhile, their cores contained mostly 
apoptotic/dead cells, which demonstrated the consequences of diffusion 
constraints in oxygen supply.  To model the effect of such molecular diffusion 
constraints, nutrient availability inside the 3D constructs can be estimated from a 
simple mass transfer simulation based on diffusion and consumption rates of 
oxygen and relevant metabolites. With reference to a hepatocyte spheroids model 
[105, 106], increasing spheroid sizes would enlarge the core area, which would 
experience oxygen levels below the critical survival threshold.  
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2.3.4 Perfusion incorporation in bioreactors 
Conventional flask cultures involve manual changing of medium, which is 
referred as fed-batch. The process of medium change involved sudden removal of 
metabolites and endogenous factors and sudden addition of nutrients. Between 
medium changes, there will be a gradual decrease in nutrients and a gradual 
build-up of metabolites. Thus fed-batch cultures will result in inconsistent 
environment throughout the culture period (Figure 2.8). On the other hand, 
perfusion enables a continuous supply and removal of nutrients and metabolites 
respectively, permitting a consistent environment during the whole culture period 
(Figure 2.8). The consistency will also allow better control of operational 
parameters like pH and oxygen. There are two classifications of perfusion: total 
and partial [107], as seen in Figure 2.9 (adapted from [108]). For total perfusion, 
the construct is typically homogenously and densely packed, such that the entire 
cross-sectional area is equally occupied. The perfused flow will then flow 
through this construct uniformly. Partial perfusion occurs in non-homogenously 
packed constructs or in constructs that are freely suspended in culture medium. In 
non-homogeneously packed constructs, there are channels with lower flow 
resistance, which will promote more fluid flow through these regions of lower 
resistance (i.e channels in constructs and regions unoccupied by suspended 
where  D:  Diffusion coefficient of oxygen within aggregate 
 H: Henry constant of oxygen from air to medium 
 PO2: Partial pressure of oxygen in the air 
 P*:  Critical pressure of oxygen for cell survival 
…… Equation 2.1 
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constructs) while less fluid will flow through regions with higher flow resistance, 
resulting in a phenomenon of partial perfusion. Total and partial perfusion will 
result in different transport profiles and microenvironments within the cardiac 




Figure 2-8 Exemplary illustration of (a) nutrients, and (b) metabolites 
levels in non-perfused (red solid line) and perfused (blue dotted lines) 
cultures 
Amount of 
fresh medium  
Critical level 
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In general, higher cell numbers were achieved in perfused cultures than 
conventional static cultures; and the expansion efficacy obtained in the perfused 
systems is similar to that achieved in spinner flasks [94]. Cell distribution within 
a construct was more homogeneous and the cell metabolism was more aerobic in 
perfused cultures than static and spinner flask cultures. This is because perfusion 
can modulate oxygen availability inside the bioreactor [94, 99, 109]. However, 
total and partial perfusion can give rise to drastically different transport profiles 
within the construct [107]. Under total perfusion, oxygen cannot be transported 
into regions further from construct periphery efficiently, resulting in lower cell 
density and viability than those along the peripheral surfaces. One solution to 
alleviate this problem is to increase the environmental oxygen level, thus 
providing enough oxygen to meet the minimum survival threshold in deeper 
regions of the construct. In partial perfusion, medium will flow through regions 
of lower resistance preferentially, resulting in significantly higher flow rates. 
Such regions of low resistance include channels and pores in constructs, regions 
with lower cell numbers and, for the case of suspended constructs, the outer 
regions around the suspended constructs. When the presence of low-resistance 
(b) (a) 
Figure 2-9 Illustration of (a) total perfusion with uniform flow through 
a homogeneous construct, and (b) partial perfusion where non-uniform 
flow results from a non-homogeneous construct [108] 
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regions is insignificant, the construct is akin to having uniform resistance and will 
result in a total perfusion system. Otherwise, cells will be more densely 
distributed along the peripheral surfaces that are exposed to low-resistant regions 
and transport beyond the peripheral surfaces will be predominantly diffusion and 
not convection. This scenario will be similar to that in non-perfused systems. 
In several bioreactor designs, it has been shown that incorporating perfusion can 
improve cardiomyocyte differentiation and maturation, thus it is beneficial to 
producing cardiac constructs for clinical applications. Perfused bioreactor has 
enhanced cardiomyocyte differentiation of murine ESCs due to a more consistent 
control of environmental factors like pH, glucose and lactate concentrations 
[110]. Besides inducing more cardiac differentiation, perfused cultures can also 
improve cardiomyocyte maturation. For instance with perfused environment, 
cardiac constructs of neonatal rat cardiomyocytes showed more uniformed 
distribution [94] and better contractile properties like higher contraction 
frequencies and twitch forces than non-perfused cultures [111, 112]. 
Considering the different parameters involved in bioreactor designs, the 
advantages and disadvantages of the bioreactors, which are discussed, for large 
scale cell proliferation and cardiomyogenesis of embryonic stem cells is 
summarised in Table 2.2. 
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Table 2-2 Summary of the advantages and disadvantages of various 
bioreactor configurations 





 - Well-mixed 
environment 
 - Convective 
nutrient transport




 - Higher cell 
proliferation and 
viability
 - Better uniformity 
in cell expansion 
and 
cardiomyogenesis
 - High shear 
envrionment
 - Cell damage and 
death
RCCS  - Well-mixed 
environment
 - Convective 
nutrient transport 
 - Negligible or 
shear environment
 - Higher cell 
proliferation and 
viability
 - Better uniformity 
in cell expansion 
and  
cardiomyogenesis








 - Well-mixed 
environment 
 - Convective 
nutrient transport
  - Higher cell 
proliferation and 
viability
 - Better uniformity 
in cell expansion 
and  
cardiomyogenesis
 - Less efficient 
nutrient transport 
than spinner flasks 
and RCCS






 - Consistent 
environment over 
time
 - Better uniformity 
in cell expansion 
and 
cardiomyogenesis
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2.4 Using 3D substrate 
For easier handling of cells in scalable and dynamic bioreactors, the use of 
substrate for cardiac and progenitor cell attachment will be required. Moreover, 
higher cell densities can be achieved with 3D constructs than a 2D culture using 
the same vessel volume [113]. These constructs also provide a 3D environment, 
which better mimics the in vivo environment, enabling cell-cell and cell-matrix 
interactions in all directions. ESCs have been cultured as 3D cellular aggregates 
through suspended EB formation, cell seeding in a 3D scaffold and encapsulation 
in a hydrogel. When using substrates for cell culture, choice of the substrate 
material and scaffold design to be used for cardiomyogenesis must be considered.  
To scale up cardiomyogenesis of human and murine ESCs in bioreactors, many 
studies formed and cultured EBs without attachment on any substrate material [6, 
91, 114-118]. However, cellular products derived from this method are highly 
dependent on bioreactor operational parameters such as rotation and shear 
environment. The resulting variations in the cellular aggregate population will 
impose difficulties in controlling cardiomyocyte differentiation and maturation. 
Besides using the substrate-free EB formation method for cardiomyogenesis, 
biomaterial scaffolds and substrates that enable 3D culture in bioreactors can also 
be utilised. Under the dynamic/suspension bioreactor systems, control of the cell 
aggregates’ properties and process scalability can be more readily achieved [5, 
119].  Alternatively, ESCs, adult stem cells and cardiomyocytes can be 
encapsulated in hydrogels for differentiation in bioreactors [120-125]. 
Encapsulation in hydrogels, such as Ca-alginate, provides better control of the 
size of aggregates during proliferation and can maintain the culture over a longer 
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period [124-126]. The hydrogels also provide a protective barrier against any 
detrimental environment effects in the dynamic bioreactors like high shear stress.  
An important consideration when selecting a suitable substrate for cell culture is 
the substrate material. The material should be biocompatible and can be sterilised 
prior to usage in cell culture. For cardiac constructs, mechanical properties of the 
selected material must also be similar to the myocardium as there should be no 
compromise in the contractile ability when transplanted. For instance, a post-
mortem human ventricle has a passive bulk modulus of 0.25 GPa and shear 
modulus of 60 – 148 kPa. [127]. Therefore, the material would preferably have 
similar Young’s modules, tensile strength and stiffness. The extent and rate of 
material degradation must also be suitable for the application. Upon degradation, 
the material should not exude any cytotoxic components.  
The materials commonly used for synthesizing substrate are classified into two 
main types: (1) naturally derived polymers and (2) synthetic polymers. Naturally 
derived polymers include alginate and collagen, and can usually facilitate cell 
attachment and maintain cell differentiation [128-131]. However, compared to 
the substrates made from synthetic polymers, the mechanical properties of natural 
polymers are more difficult to control and less consistent due to high inter-batch 
variability based on the resources. Meanwhile, using synthetic polymers like 
poly(ethylene glycol), poly(lactic acid) (PLA) and phosphoester allows better 
control of mechanical properties through tuning parameters of the synthesis 
process. However, cell adhesion is not as efficient on synthetic substrates as on 
those from naturally derived polymers. To enable better adhesion and enhanced 
cardiomyogenesis, studies have incorporated extracellular matrix (ECM) derived 
proteins and peptides like laminin, gelatin and Arg-Gly-Asp (RGD), on both 
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naturally derived and synthetic polymer chains [132-135]. For instance, 
incorporating RGD peptides on substrates has improved cardiomyocyte viability 
and enhanced their contractile performance [123]. The physical anitropsy and 
mechanical properties of synthetic polymer substrates can also be tuned to 
desired configurations for directing cell attachment and alignment, which can be 
beneficial for improving the contractile properties of cardiac construct [133, 134]. 
This is demonstrated on grooved or channelled surfaces and anisotropic geometry 
of the scaffolds where alignment and contractile properties of cardiomyocytes 
were improved [136-138].  
2.4.1 Alginate hydrogel encapsulation 
As previously mentioned, hydrogel encapsulation is one method to enable 3D cell 
culture for cardiomyogenesis. Hydrogel is a class of highly hydrated scaffold 
which meets the desirable requirements of biomaterials for cardiac tissue 
engineering in terms of: (1) biocompatibility, (2) starting materials that can be 
sterilised, (3) controllable biodegradability, (4) soft and pliable nature, (5) 
modulation of mechanical properties, and (6) high permeability for efficient 
transport of nutrients and metabolites [139-141].  One form of hydrogel 
encapsulation is in the form of small spherical beads, where cells are uniformly 
distributed within these beads. Such configuration allows 3D culture with 
enhanced exchange of soluble factors between the environment and scaffold 
interior as spheres have the highest surface area to volume ratio. Moreover, 
spherical hydrogels have the potential to allow direct injection into a wound site.  
Use of alginates for hydrogel synthesis has been well-established in the tissue 
engineering field. Alginate is a negatively charged polysaccharide derived from 
brown seaweed and comprises of alternating chains of α-L-guluronic and β-D-
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mannuronic acid residues. Alginate solution initially exists in liquid state and 
upon the presence of divalent ions, usually Ca2+, the polymer chains will 
crosslink, forming a 3D network and giving rise to a solid state with an oriented 
and regular structure. This 3D network can be roughly described by an “egg-box” 
model [142] as illustrated in Figure 2.10. The solid circles represent calcium ions 
which bind to chains of α-L-guluronic acid residues of alginate polymers, 
resulting in V-shaped structures. Meanwhile, β-D-mannuronic acid residues 
which are not bound to calcium ions will be free-hanging chains at the ends of 
this “egg-box” structure of guluronic acid residues and calcium ions.  
 
Mechanical and transport properties of alginate hydrogel depend on the extent of 
inter-chain binding and porosity. These are controlled by several synthesis 
parameters like alginate solution concentration, multivalent cation concentration, 
duration of crosslinking, temperature and stirring [139]. The alginate hydrogel 
Low Ca2+ model High Ca2+ model 
Figure 2-10 Schematic diagram of the ‘‘egg-box’’ models in low and 
high calcium ions concentration. Adapted from Simpson et al. [142]. 
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properties are highly reproducible under the exact same conditions, making it a 
favourable candidate for usage in bioreactors and tissue engineering. However, 
multivalent ions may escape the 3D network and cause accelerated degradation 
under high shear stress environment or during prolonged culture. Thus, gelatin 
could be added during the encapsulation process to increase network integrity. 
Incorporation of gelatin will enable cell-mediated contraction and packing of the 
crosslinked alginate network [143], thus improving network integrity and 
allowing long term culture. Alginate hydrogel has been utilised for 
cardiomyocyte differentiation and maturation [130]. Novel composite hydrogels 
of alginate and materials alike can be used to improve contractile properties of 
the cardiac constructs. For instance culturing neonatal rat cardiomyocytes in 
composite hydrogels of alginates and hyaluronic acid, barium, RGD or nanowires 
enabled better structural maturation and contractile properties than in pure 
alginate hydrogels [131, 144-146]. Utility of alginate encapsulation for 
cardiomyogenesis has also been demonstrated in bioreactors of different 
configurations like spinner flasks, rotary vessels and perfused bioreactors [92, 
126, 147, 148] . 
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2.5 Incorporation of mechanical and electrical stimuli in 
bioreactors for cardiomyogenesis 
2.5.1 Mechanical stimulation for cardiomyogenesis 
The pumping action of the myocardium is based on synchronised contractile 
motion of cardiac muscles cells. There are two main stages during cardiac 
pumping. First, the two atria will contract simultaneously during the diastole 
stage, resulting in delivery of blood and filling of the ventricles. During the next 
systole stage, the ventricles will produce strong, rhythmic contractions which will 
pump the blood through the aortic and pulmonary valves and deliver blood to 
other parts of the body. While the blood is being pumped from the ventricles, 
blood will start flowing into and fill the atria. After the blood has been pumped 
from the ventricle, the ventricular muscle will relax, bringing another onset of 
this cycle. These pumping actions require that the cardiomyocytes, which are to 
be used for clinical therapies, possess mechanical properties suitable for 
synchronised contraction of a normal myocardium which experiences pressure 
ranging from 10 to 130 mmHg. 
Mechanical stimuli can affect cellular development such as differentiation and 
phenotype modulation. Such effects are even more significant in mechanically 
dynamic tissues like cardiac tissues. Mechanical stimuli can take on forms of 
cyclic strains, pressure or shear stress. Studies have demonstrated that 
incorporation of 1 Hz cyclic stretch at 1 – 20% of the cardiac construct’s space 
length could provide cues that affected cellular expressions and functionalities 
such as a 40% increase in α-sacromeric actin gene expression, a 14 – 44% 
decrease in twitch duration and more organised cell elongations and alignment 
[149-152]. With the cyclic stretch, cardiomyocyte alignment was also more 
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organised with a general orientation that was transverse to the stretch [153]. Thus 
incorporation of mechanical stimuli could produce cardiac constructs with 
contractile properties that would better mimic the native cardiac muscle. 
Bioreactors have made use of designs that allow cyclic stretching of the scaffolds 
on which the cells are seeded. This type of design uses either a pulsing flow of 
fluid to cause alternating expansion and contraction of scaffold volume or direct 
stretching of the scaffolds, as illustrated in Figure 2.11. Cyclic stretching of 
scaffolds will induce cyclic strains on the seeded cells, providing mechanical 
cues for cardiac differentiation. ESCs and BM-MSCs under these cyclic strains 
have been reported to give elevated cardiac gene expression [9, 10, 154, 155], 
showing that mechanical stimuli can enhance cardiomyogenesis from cell sources 
like stem cells. Meanwhile, this type of mechanical stimuli can also improve 
contractile properties of cardiomyocytes such as better cell alignment and higher 
contracting forces [156, 157].  
 
(b) 
(a) Expansion and contraction of scaffold volume 
Direct stretching of cardiac construct 
Figure 2-11 Examples of designs to cause cyclic stretching of cardiac 
constructs 
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The other method of providing mechanical cues is via pulsatile perfusion through 
the cardiac constructs [8, 147]. Brown et al. [8] has developed one such 
bioreactor where the cardiac construct was sandwiched in between two gaskets, 
and medium would flow perpendicularly through the seeded cells (Figure 2.7 (b) 
in Section 2.3.1). This flow would cause shear stress on the cells and thus, 
provide mechanical cues for differentiation and maturation. Neonatal rat 
cardiomyocytes, when cultured in this bioreactor, has observed better maturation, 
i.e. increased hypertrophy and elongations. 
As seen from these designs, components producing mechanical stimulation can 
be incorporated into the bioreactor to enhance cardiomyogenesis and produce 
cardiac constructs with better contractile properties for clinical applications.  
2.5.2 Electrical stimulation for cardiomyogenesis 
During cardiac pumping, natural pacemaker cells in sinoatrial (S-A) node will 
produce a wave of electrical excitation. The electrical signal will then be 
transmitted to atrioventricular (A-V) node through a coordinated contraction of 
the atria. Thereafter, the A-V node will spread the electrical excitation (action 
potential) via ventricles' network of nerve fibres to obtain ventricular 
synchronised mechanical contraction. Therefore, for cardiomyocytes to be 
suitable for clinical transplantation, they must be able to conduct electrical 
signals that support normal myocardium activities. Furthermore, during 
embryonic development, there are endogenous electromagnetic fields which 
affect the development like placement of components [158, 159]. From this, it 
can be deduced that using electrical stimuli can improve cardiac differentiation 
and maturation. 
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Studies have demonstrated the benefits of electrical stimulation on both cardiac 
differentiation and maturation. When ESCs are subjected to electrical treatments 
ranging from 0.1 – 1 V/mm, they displayed a 5 – 10% increase in number of 
beating areas and a 6-fold increase in cardiac Troponin-T gene expressions [160-
162]. Similarly, when cardiac constructs of neonatal rat cardiomyocytes are 
placed in platforms with ionic buffer or arrayed electrodes, the electrical cues 
improved their contractile properties lowering the excitation threshold, and 
produced better cardiomyocyte alignment and well-formed striations [163-167].  
  






3 Using a novel rotary 
perfused bioreactor for ESC 
cardiomyogenesis  
  
As presented in Teo et al (2014), Biotechnology Letters. 36 (5): 947-960 
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3.1 Background 
As previously mentioned, cardiomyocytes have limited proliferative capacity, 
thus the human cardiac muscle is unable to regenerate itself on the onset of 
myocardial infarction. This presents a major challenge in finding treatment for 
patients to restore full cardiac functionality in the infarcted areas. A potential 
clinical treatment for myocardial infarction is cellular therapy and cardiac 
regeneration. However, utilising cellular therapy for cardiac regeneration is met 
with limitations such as the production of clinically relevant cell numbers, 
cardiac functionality and tissue integration. A therapeutic course for myocardial 
infarction requires a minimum of 108 – 109 functional cardiomyocytes in each 
treatment [3]. Such high numbers are required for efficient replacement of 
damaged or dead ventricular cardiomyocytes and substantial improvement in 
function of the infarcted heart. To achieve the production of cardiomyocytes in 
high cell numbers, the usage of highly proliferative cells as cell sources, such as 
ESCs, have to be considered. 
In order to obtain clinically relevant numbers of cardiomyocytes, scale-up of cell 
culture bioprocesses is necessary. Conventional differentiation of ESCs requires 
multiple steps of ESC expansion, EB formation and finally replating of EBs for 
directed cardiomyocyte differentiation. As TCPs usually have size limitations, 
large-scale expansion of ESC cultures involves large quantities of vessels. 
Therefore, the multistep culture process and the large number of vessels will 
make this conventional differentiation process laborious and highly dependent on 
inter-batch variability. 
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Given these issues, 3D cultures and bioreactors have been utilised as more 
efficient platforms with enabled control of environmental conditions for scaling 
up production of cell products and to ensure better reproducibility. In developing 
such platforms, one must consider the hydrodynamic profiles and feeding 
strategy, as they will affect the cell’s microenvironment and thus cellular 
activities. Studies have shown that homogeneous environments, as seen in 
spinner flasks [6, 7, 42, 89], or rotary vessels [90, 91] could circumvent potential 
problems faced by TCP static cultures such as spatial gradients of physiochemical 
concentrations [168, 169]. Improved homogeneity in bioreactors could result in 
better reproducibility of cardiomyocyte yield. In contrast, conventional cultures 
usually require manual medium exchange, known as a fed-batch method. 
Periodic medium changes will cause fluctuations in the cell microenvironment 
which make cause detrimental effects to the cells. Conventional culture practices 
also makes monitoring and control of culture parameters difficult for large scale 
culture and will affect the reproducibility between different batches. Perfusion, 
which can be incorporated into bioreactors, can provide a more consistent 
environment throughout the culture period [42].  
Arising from these needs, our laboratory has previously designed a rotary wall 
bioreactor incorporated with perfusion [170, 171]. Such bioreactor design was 
hypothesised to provide a low shear stress and continual medium exchange that 
were preferred for inducing cardiomyogenesis and improving uniformity within 
3D cardiac constructs. As briefly illustrated in Figure 3.1, medium was perfused 
from holes in a central perfusion inlet stick and undergo radial mixing. To allow 
efficient oxygen and carbon dioxide exchange between the culture medium and 
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the controlled incubator’s environment, the culture vessel wall was made of an 
air-permeable membrane.  
 
In this chapter, this novel bioreactor was used for directing cardiomyogenesis in 
mESCs. To evaluate the impact of hydrodynamics in the perfusion system, the 
efficiency in driving cardiomyocyte differentiation of encapsulated mESCs in this 
platform was compared to those in conventional TCP and commercialised RCCS 
bioreactor cultures. These systems differed in their hydrodynamic profiles such as 
static and dynamic environments, and fed-batch and perfused feeding strategy.  
Through this study, I hope to investigate the feasibility of using this novel 
bioreactor to produce cardiomyocytes with clinical relevant numbers from cell 
sources such as embryonic stem cells. Murine ESCs were used as a model to 
study the overall impact of a novel design perfused bioreactor on 
cardiomyogenesis and these results would help to evaluate the feasibility and 
benefits of this novel bioreactor toward the bioprocess efforts in pluripotent stem 
cell cultures.  
  
Figure 3-1 Brief illustration of culture vessel in novel rotary perfused 
bioreactor 
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3.2 Materials and methods 
3.2.1 Maintenance of murine ESCs 
Murine ESCs (mESCs, cell line: E14TG2a, ATCC) were maintained in cultures 
seeded on 0.1% porcine-gelatin (Sigma) coated vessels with an ESC maintenance 
medium. The ESC maintenance medium was made up of high-glucose Dulbecco 
Modified Eagle’s Medium (DMEM) (Gibco, Invitrogen), 10% heat-inactivated 
fetal bovine serum (FBS) (Gibco, Invitrogen), 0.1 mM 2-mercaptoethanol 
(Sigma), 2 mM L-glutamine (ATCC, LGC Standards), 1x penicillin-streptomycin 
(ATCC, LGC Standards) and 1000 U/mL leukemic inhibitory factor (LIF) 
(Chemicon, Millipore), which served to prevent spontaneous differentiation and 
thus maintain ESCs’ pluripotency. To ensure enough nutrients for ESCs’ rapid 
proliferation and pluripotency, medium was changed daily.  
When mESCs reached 70 – 80% confluency, typically after 2–3 days of seeding, 
passaging was conducted. Cells were first washed with PBS twice prior to 
enzymatic digestion by 0.05% trypsin-EDTA. After enzymatic digestion, ESCs 
would detach from TCP surface. Trypsin was then inactivated by fresh 
maintenance medium and cells were separated from the solution via 
centrifugation at 200 g for 5 mins. The cell pellet was re-suspended and 
uniformly mixed by gentle pipetting to ensure uniform singular cell distribution. 
Finally the re-suspended cells were seeded onto a newly gelatin-coated TCP for 
further culturing. Uniformity was required to ensure that the newly seeded ESCs 
would proliferate into colonies with more uniformity, thus reducing the 
variability in cell phenotype due to events like undesired spontaneous 
differentiation of larger colonies.   
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3.2.2 Preparation of HepG2 conditioned medium (HepG2-CM)  
HepG2-CM was shown to provide cues to direct mESCs towards mesodermal 
lineage [79, 80]. The conditioning to mesodermal lineage will then help to 
increase cardiomyocyte yield from mESCs. To obtain HepG2-CM for priming 
mESCs towards mesodermal lineage, medium was collected from HepG2 
cultures and several reagents were added prior to usage. Before collection of 
media, human hepatoma cells (cell line: HepG2, ATCC) were first routinely 
cultured and passaged to ensure stable phenotype. Thereafter, HepG2 was seeded 
on uncoated TCP flasks at 5 x 104 cells/cm2. Normal HepG2 maintenance 
medium was used for HepG2 culture and consisted of high-glucose DMEM, 10% 
heat-inactivated FBS and 1x penicillin-streptomycin. After 4 days of culture, the 
medium in HepG2 culture was collected and sterilised by passing through a 0.22 
µm filter. This collected medium could then be used to make HepG2-CM or be 
stored at -80oC.  
To make HepG2-CM, several components must be added to the collected 
medium. First, there was supplementation of 0.1 mM of 2-mercaptoethanol, 2 
mM of L-glutamine and 1000 U/mL of LIF were added. The supplemented 
medium was finally mixed with equal volume of ESC maintenance medium to 
make the final HepG2-CM.  
3.2.3 Alginate encapsulation of mESCs 
Encapsulation of mESCs in alginate hydrogels required two solutions: alginate 
polymer solution and Ca2+ cross-linking solution. Alginate polymer solution was 
made of 1.1% alginic acid sodium salt (Sigma) and 0.1% porcine gelatin (Sigma) 
in PBS solution, while the Ca2+ crosslinking solution consisted of 100 mM 
calcium chloride (Sigma), 10 mM N-(s-hydroxyethyl) piperazine-N-(2-ethane 
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sulfonic acid) (HEPES) (Sigma) and 1% tween (Bio-Rad) . The pH of both 
solutions were adjusted to pH 7.2 and sterilised by passing through 0.22 µm 
filter.  
To prepare cells for encapsulation, mESCs were homogenised in alginate 
polymer solution at 2.5 x 106 cells/mL. The cell suspension was passed through a 
sterile tubing and 25-gauge needle, and slowly dripped by peristaltic pumping 
into the crosslinking solution (Figure 3.2 (a)). In brief, the dripping was done at a 
height of 50 mm from surface of the crosslinking solution. The height was 
required as alginate gelling would happen upon contact with the crosslinking 
solution. 50 mm height would give sufficient time for formation of spherical 
hydrogels (beads) where their diameters averaged around 2.5 mm. After alginate 
gelation, the encapsulated cells were washed thrice with PBS to remove residual 
Ca2+ prior to culture. 
 





Figure 3-2 (a) Schematic diagram of procedure in encapsulation and 
culture of mESCs in different bioprocess platform. (b) Timeline of 
different stages of cardiomyogenesis in the platforms 
Culture of mESCs 
Encapsulation of cells 
Culture in different platforms 
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3.2.4 Comparative study in various culture platforms 
Encapsulated mESCs were cultured in three different culture platforms with 
different hydrodynamic profiles and feeding strategy. They were (1) T-175 flasks 
(static and fed-batch), (2) 50 mL HARV vessels (dynamic and fed-batch), and (3) 
our novel perfused bioreactor (dynamic and perfused), as illustrated in Figure 3.2 
(a). As there was no mixing and minimal fluid flow in T-175 flask cultures, they 
were considered static cultures. Meanwhile, HARV and perfused bioreactor 
cultures are coined as dynamic cultures since they provided mixing and moving 
fluid inside the culture vessels. A total of 500 hydrogel beads were added and 
cultured in each platform, and two independent experimental runs were 
conducted for each setup. 
For cardiomyocyte differentiation of mESCs, the cells were subjected to 
expansion and priming towards mesodermal lineage for the first three days by 
using HepG2-CM for culture. The priming towards the mesodermal lineage was 
then followed by the directed differentiation toward cardiomyocytes. In directed 
differentiation, Iscove's modified Dulbecco's medium (IMDM) basal medium 
was used over the conventional DMEM for its reported higher levels of 
cardiomyogenesis by Guan et al. [172]. Therefore, the differentiation medium 
consisted of high-glucose IMDM (Gibco, Lifetech), 20% heat-inactivated FBS, 2 
mM L-glutamine, 1x penicillin-streptomycin, 450 µM 1-thioglycerol and 0.25 
µM Cardiogenol C (Sigma). Cardiogenol C is a diaminopyrimidine used as 
cardiomyogenic-inducing agent through upregulation of Wnt11 expression [87]. 
As such, the final constituted medium was used for the remainder of 
differentiation period, typically 18 days. Throughout the 21 days of 
expansion/priming and differentiation, medium was replaced daily in both TCP 
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flasks and HARV cultures, while medium was perfused through the perfused 
bioreactor at 50 ml/day. The whole process is summarised in Figure 3.2 (b). 
Random beads were sampled on Day 21 and 25 for evaluating cell viability, 
aggregates’ sizing and percentage of cells differentiated to cardiomyocytes. Cells 
were also extracted from the alginate hydrogel on Day 3, 6, 10, 16 and 21 for 
evaluation of cell proliferation and cardiac gene expressions.  
3.2.5 Extraction of cells from encapsulation 
To extract encapsulated cells from alginate beads, the alginate gel network was 
disrupted by a dissolution buffer. A dissolution buffer was made of 50 mM tri-
sodium citrate dehydrate (Sigma), 77 mM sodium chloride (Sigma) and 10 mM 
HEPES (Sigma). Disrupting the alginate gel network produced a liquid solution 
with cell suspensions. The extracted cell suspension was then centrifuged at 200 
g for 5 mins and washed twice with phosphate buffered saline (PBS) before 
further analysis. 
3.2.6 Microscopic visualisation and sizing of encapsulated cell 
aggregates 
Encapsulated cells were observed with an inverted optical microscope (Leica 
DMil) and their 10x magnification images were captured with accompanying 
camera (Olympus DP50). Encapsulated aggregates in the hydrogel were observed 
to take on a general shape of an ellipse. To size the encapsulated aggregates, the 
length (major diameter of the ellipse) and width (minor diameter of the ellipse) of 
each encapsulated cell aggregates were measured with the analysis^D software 
(Olympus). Thereafter these measurements for each aggregate were averaged and 
sorted into the respective size bins to obtain a size distribution in the different 
culture platforms. A total of 80 – 100 aggregates encapsulated in four randomly-
sampled hydrogels were measured and binned for each culture platform. 
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3.2.7 Live/Dead Staining 
Cell viability of encapsulated aggregates was analysed using LIVE/DEAD 
Mammalian Cells Viability/Cytotoxicity Kit (Invitrogen, UK) qualitatively. Five 
beads were collected from each run and were washed with PBS twice. They were 
next incubated with 2 µM calcein-AM and 4 µM EthD-1 for 30 mins at room 
temperature in the dark. Calcein-AM will stain for intracellular esterase activities 
in living cells while EthD-1 will stain for the nuclei of the dead cells. After 
incubation, the beads were washed with PBS twice to remove any residual dyes. 
They were then observed under an inverted fluorescence microscope (Olympus 
BX51, Olympus) in the dark for the viability staining. Finally images were 
captured using the accompanying imaging camera (F-view II, Soft imaging 
system) and analysis^D software. 
3.2.8 DNA quantification 
To determine the number of cells encapsulated in each bead, the amount of 
double stranded DNA content in a sampled population of beads was measured. 
DNA content was measured by using the Quant-IT PicoGreen dsDNA Reagent 
and Kit (Invitrogen). At different time points (Day 3, 6, 10, 16 and 21), 5–10 
beads were used for sampling. The cells were extracted as described in Section 
3.2.5. The cells were then incubated overnight at 37oC in 50 μg/ml proteinase-K 
(Sigma) solution containing 100 mM dibasic potassium phosphate (Sigma, pH 
8.0) for protein digestion. After incubation, Proteinase-K was heat-inactivated by 
incubating at 90oC for 10 mins. The solution was next centrifuged to remove any 
cell debris as a pellet and to collect double-stranded DNA (dsDNA) in the 
supernatant. The PicoGreen reagent was diluted accordingly to the 
manufacturer’s instruction. Thereafter an equal volume of diluted PicoGreen 
reagent in 1x TE buffer (pH 7.5) was added to the dsDNA. Last but not least, 
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fluorescence was produced by the binding of PicoGreen reagent to the dsDNA 
and measured with a fluorometer (MFX microplate fluorometer; Dynex 
technologies). A cell number-fluorescence standard curve was also prepared to 
interpolate the sampled cell numbers. 
3.2.9 Quantitative PCR 
Cardiac differentiation of mESCs was determined with gene expression levels 
measured by quantitative polymerase chain reaction (PCR). Total RNA was first 
isolated from extracted cells using RNeasy kit (Qiagen) and RNase-free DNase 
kit (Qiagen) according to the manufacturer’s instructions. RNA collected was 
quantified with a UV spectrophotometer (Eppendorf). After RNA quantification, 
1 µg of RNA was used for synthesis of first strand of complementary DNA 
(cDNA). cDNA was synthesized using a Reverse Transcription Kit (Promega).  
To compare cardiomyogenesis in different culture platforms, quantitative PCR 
was carried out with SensiFASTTM SYBR Hi-ROX Kit (Bioline). In brief, 100 ng 
cDNA was added to 10 µl of mastermix, 400 nM of primers. Nuclease-free water 
was also added to make up to a final volume. The mixture underwent PCR 
amplification process and measurement in StepOneTM Plus (Applied 
BiosystemsTM). The PCR process involved initial denaturation at 95oC for 2 mins 
and an amplification stage with 40 cycles of denaturation at 95oC for 5 secs and 
annealing/extension at 60oC for 30 secs. Different genes were analysed with the 
different primers (Invitrogen), as shown in Table 3.1. PCR end products were 
also analysed with electrophoresis in 2% agarose gel and ethidium bromide and 
melt curves were conducted after every PCR run to ensure the absence of any 
side products and formation of primer-dimers. After checking that all primers 
have similar amplification efficiencies under the parameters used, the gene 
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expressions among different culture platforms were normalised to the 
endogenous control gene, GAPDH, and then to the static controls on Day 3 
(which corresponded to the start of directed cardiac differentiation) and finally 
compared using 2-∆∆CT method. The 2-∆∆CT method has been widely used in 
determining relative gene expressions in samples to that in the control groups and 
has been described in detail by Schmittgen et al. [173]. Briefly, the fold change of 
target gene expression in sample from that in control was calculated with 
Equations (3.1) and (3.2).  
∆∆𝐶𝑇 = [𝐶𝑇,𝑠𝑎𝑚𝑝𝑙𝑒(𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒) − 𝐶𝑇,𝑠𝑎𝑚𝑝𝑙𝑒(𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑒𝑛𝑒)] 
− [𝐶𝑇,𝑐𝑜𝑛𝑡𝑟𝑜𝑙(𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒) −  𝐶𝑇,𝑐𝑜𝑛𝑡𝑟𝑜𝑙(𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑒𝑛𝑒)] 
 …. Equation (3.1) 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 𝑜𝑓 𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒 = 2−∆∆𝐶𝑇   …. Equation (3.2) 
 , where CT refers to the threshold cycle from quantitative PCR data. 
Table 3-1 List of studied genes and their respective primers in studying 
effects of hydrodynamics on cardiomyogenesis 











 Oct-4 TGTGGACCTCAGGTTGGACT CTTCTGCAGGGCTTTCATGT
 
- 78 - 
 
3.2.10 Flow cytometry 
To quantify the percentage of mESCs differentiating to cardiomyocytes in the 
different culture set-ups, flow cytometry was used to determine the percentage of 
cells positive for expression of cardiac troponin-I.  
First, the alginate network in hydrogel was depolymerised as described in Section 
3.2.5. The extracted cells were then fixed in 4% paraformaldehyde (Sigma) for 15 
mins and permeabilised in 0.1% Triton-X (Ultrapure grade, USB Corporation) 
for another 15 mins at room temperature. Thereafter, the cells were resuspended 
in PBS containing 5% goat serum, 0.1% Triton-X and 1% sodium azide to a 
concentration of 1 – 5 x 106 cells/ml. 100 µl of the resulting cell suspension was 
transferred to a new tube, and 2 µl of cardiac Troponin-I primary antibody (H-41, 
Santa Cruz Biotechnology) was added. It was then incubated for 2 hours at 4oC. 
After incubation, the cells were washed twice with cold PBS and incubated with 
100 µl of FITC-conjugated secondary antibody (Santa Cruz Biotechnology) 
diluted in 3% bovine serum albumin in PBS for 1-hour at room temperature in 
the dark. Next, the cells were washed twice with cold PBS. To store the cells 
prior to flow cytometry, the cells were re-suspended in PBS consisting of 2% 
paraformaldehyde, 3% bovine serum albumin and 1% sodium azide and kept in 
4oC. Finally, stained cells were analysed on the flow cytometer (FACSCalibur, 
BD Biosciences) and the percentage of positively stained cells were quantified in 
in a flow cytometry analysis software FlowJo (Tree Star). 
3.2.11 Immunocytochemistry of sacromeric α-actinin and connexin-43 
networks 
Encapsulated cells from different culture platform were fixed with 4% 
paraformaldehyde (Sigma) in PBS for 1 hour at room temperature. Next, they 
underwent a serial dehydration with increasing concentrations of 50%, 70%, 
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90%, 95% and 100% ethanol and finally pure xylene. They were then immersed 
in paraffin-saturated xylene overnight at room temperature to condition for 
paraffin embedding. On the following day, these dehydrated samples were 
paraffin-embedded with Paraplast (Sigma) and sectioned to 5 µm slices. Before 
immunostaining was conducted, the sectioned sample underwent a serial 
rehydration, starting immersion in pure xylene and then decreasing 
concentrations of ethanol (100%, 95%, 90%, 70% and 50%). Finally they were 
incubated in an antigen-retrieval buffer (10mM tri-sodium citrate dihydrate, pH 
6.0, Sigma) at 96oC for 30 mins.  
After antigen retrieval, immunostaining was carried out. The samples were first 
incubated with 10% goat serum for 45 mins at room temperature to block out all 
unspecified binding. They were then incubated overnight with primary antibodies 
of sacromeric α-actinin (EA-53, Santa Cruz Biotechnology, 100x dilution in 
primary diluents of 0.1% sodium azide and 1% bovine serum albumin in PBS) or 
connexin-43 (CXN-6, Santa Cruz Biotechnologies, 400x dilution in primary 
diluents) at 4oC. Thereafter, the slides were washed with PBS thrice prior to 1 
hour-incubation with FITC-conjugated or TRITC-conjugated secondary 
antibodies respectively (100x dilution in 1% bovine serum albumin in PBS) at 
room temperature. The slides were then washed with PBS on a shaker for 10 
mins. This washing step was repeated thrice to ensure that the stained samples 
were free of residual antibodies. Last but not least, the samples were incubated 
with DAPI dye for 5 – 10 mins to stain for nuclei. The immunostaining results 
were finally imaged with fluorescence microscope (Olympus) and AxioVision 
4.0 (Olympus). 
 
- 80 - 
 
3.2.12 Statistical analysis 
All statistical analysis was conducted by using Microsoft Office Excel analysis 
tool package (Excel 2013, Microsoft). To check for significant differences in cell 
numbers (through dsDNA quantification), quantitative PCR data, and flow 
cytometry data between experimental groups, equal variances were first checked 
using F-test with 95% significance level. The results showed that there were 
unequal variances in most comparison pairs. Thus student t-test with unequal 
variances were thus used to test for inter-group differences of 95% significance. 
Error bars on the charts represent standard deviations of each group. The sample 
populations (N) represented total number of biological replicates from 2 
independent experimental runs and are indicated in the legends of each respective 
figures. 
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3.3 Results 
3.3.1 Denser and more uniform aggregates in dynamic cultures 
mESCs were initially encapsulated as a single-cell suspension, which resulted in 
uniform distribution of individual cells within an alginate bead. Each bead has an 
average diameter of 2.5 mm and a cell number of 2 x 104 cells. Over the culture 
period, these encapsulated ESCs proliferated and started to form clusters of cells 
called aggregates. In this study, the growth of these aggregates (sizes and 
densities) was monitored.  
After 3 days of cell expansion and priming towards mesodermal lineage in 
HepG2-CM, microscopic observations revealed that cells in the dynamic culture 
platforms, namely HARV and the novel perfused bioreactor, formed more 
aggregates than those in the static culture (TCP flasks) (Figure 3.3 (a – c)). 
Moreover, it was also observed on Day 21 that there was presence of cells in the 
static culture which failed to form cell aggregates (as indicated by red arrows in 
Figure 3.3 (d)). On the other hand, such observations were insignificant in the 
dynamic cultures (Figure 3.3 (e – f)).  
While a visual inspection may not clearly distinguish differences in cell 
aggregates amongst the different cultures, a more quantitative method is sought 
after. The sizes of 80–100 aggregates from each culture were evaluated by 
measuring their dimensions and binning them, as described in Section 3.2.6. 
Binning of aggregates by size helped in the evaluation of aggregates’ size 
distribution in various culture platforms and thus provided an insight into the 
uniformity of aggregate cell growth. Each bead had numerous encapsulated cell 
aggregates and each aggregate were of different sizes, despite being in the same 
bead. The distribution was as depicted as in Figure 3.3 (g). Cells in static culture 
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gave rise to a distribution where two aggregate sizes were more common 
(modes). They were the bins of 40 – 60 µm and > 220 µm. These two modes 
represented two extreme aggregate sizes that were more common in static 
cultures. Two modal aggregate sizes of 100 – 120 µm and 160 – 180 µm were 
observed in the novel bioreactor. These two values were not as drastically 
different as those observed in static cultures. Meanwhile, HARV cultures 
produced the best size distribution with only one modal size at 140 – 160 µm. 
The two extreme modal aggregate sizes in static cultures showed the larger 
variation in cell growth due to absence of mixing and hydrodynamic flows. In 
comparison, HARV and the novel bioreactor produced higher numbers of 
aggregates with higher uniformity. 
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3.3.2 Higher viability and cell numbers in dynamic cultures 
From the observed cell numbers via dsDNA quantification, it was observed that 
there were better cell growths in HARV and the novel bioreactor than in static 
cultures (Figure 3.4).  After 3 days in culture, there was minimal cell growth in 
the static cultures, producing an average cell density of 1.5 x 105 cells/bead for 
(g) 
(a) (b) (c) 
(d) (e) (f) 
Figure 3-3 (a – f) Micrographs of encapsulated aggregates in alginate 
hydrogel on Day 3 days and 21. The red arrows in (d) indicate the cells 
which failed to proliferate into cellular aggregates. Scale bar represents 
100 µm. (g) Population distribution of aggregate sizes after 21 days of 
culture. Size was calculated as an average of the aggregate’s length and 
width and binned into the respective size range.  Binning of 80 
aggregates from 4 beads cultured in the respective systems. 
Static HARV Perfused 
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the whole culture period consistently. In contrast, significantly higher cell 
numbers were obtained from HARV and the novel bioreactor at the end of 21-day 
culture period. HARV gave rise to the highest and fastest cell proliferation, where 
it produced an estimated 4 x 105 cells/bead by Day 10. This high cell density 
population was then maintained till the end of culture. Meanwhile, the cell 
growth was slower but more consistent in novel bioreactor. After 21 days, 
encapsulated cells in the novel bioreactor amounted to 3.8 x 105 cells/bead, a 
density which was similar to HARV cultures. The improved cell proliferation in 
dynamic cultures coincided with the improved uniformity and denser cell 
aggregates as described in Section 3.3.1.   
 
From the live/dead fluorescence micrographs (Figure 3.5), cell viabilities in both 
dynamic cultures were significantly better than those in static cultures. In the 
HARV and novel bioreactor cultures, all encapsulated cell aggregates from 
Figure 3-4 Cell numbers in different culture platforms. * represents 
significant difference from previous time point in the same platform. ^ 
represents significant difference from other platforms (or indicated 
platform) at the same time point. p < 0.05, N = 4 from 2 independent runs. 
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HARV and novel bioreactor cultures were highly viable, where the presence of 
dead cells was negligible. On the other hand, presence of dead cells was evident 
in the static cultures; some aggregates consisted a significant portion of dead 
cells. Comparing the cell numbers and viabilities obtained from these three 
culture platforms, lack of hydrodynamics in static environment clearly posed 
significant transport limitations in culturing 3D cardiac construct. Such impact of 
hydrodynamics could be due to the lack of nutrient transport to the encapsulated 
cell aggregates in static cultures, thus compromising cell growth and viability. 
 
3.3.3 Earlier and higher cardiac marker expressions in perfused 
platform  
To determine extent of cardiomyogenesis in different culture platforms, various 
gene expressions, indicating the different stages of ESC differentiation towards 




Figure 3-5 Live/dead fluorescence images at of encapsulated aggregates 
at day 21 in (a) static platform, (b) HARV reactor, and (c) perfused 
bioreactor. Green and red fluorescence represent live and dead cells 
respectively. Scale bar represents 100 µm. 
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represented early mesodermal lineage commitment of ESCs and specificity 
towards cardiac progenitors respectively. At each respective time point during the 
21-day culture, no significant differences in the Brachyury-T and Nkx2.5 gene 
expressions between different culture platforms were observed (Figure 3.6). 
Although all platforms gave rise to similar levels of early cardiac markers, there 
were significant differences in the expressions of late cardiac genes such as 
cardiac troponin-T (cTNT), α- and β- myosin heavy chains (MHC).  
 
Cardiac troponin is a regulatory protein complex involved in cardiac calcium 
signalling. When it is bound to calcium signalling ion, it allows interaction 
between cardiac actin filaments and myosin to achieve muscle contraction. It 
consists of three subunits: troponin T, troponin I and troponin C. In this study, an 
(b) 
Figure 3-6 Fold changes in 
expression of (a) 
mesodermal marker 
Brachyury T, and (b) early 
cardiac progenitor Nkx-2.5 
culture period. * represents 
significant difference from 
previous time point sample 
from the same platform. ^ 
represent significant 
difference from other 
platforms (or indicated 
platform) at the respective 
time point. ‘s’: static, ‘h’: 
harv, ‘p’: perfused 
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upregulation of cardiac troponin T (cTNT) on Day 6 was observed in novel 
bioreactor but not in the static and HARV cultures (Figure 3.6 (a)). This 
upregulation was transient and was absent thereafter. It was only till 21 days of 
culture where it was again upregulated in novel bioreactor. By this day, cTNT 
was also upregulated in the other platforms. However, its expression was 
significantly the highest in novel bioreactor culture. The phenomenon of an early 
transient upregulation, which was followed by a later stage upregulation was 
similar to observations made by Antin et al. [174]. cTNT was first up-regulated 
temporarily during mesodermal commitment and a late upregulation happened 
again at more localised regions in maturing cardiomyocytes during 
differentiation. 
Another type of markers for late cardiac differentiation is the contractile 
structural protein, myosin heavy chain. Cardiac myosin is a motor protein that 
moves along cardiac actin filament for generation of muscle contraction. It 
consisted of four light chains and two heavy chains, forming a dimeric structure. 
The heavy chains exist in two isoforms, α-MHC and β-MHC. These two isoforms 
differ in their ATPase activity levels and their amount of force generated in the 
muscles. On Day 16, the novel bioreactor produced an earlier upregulation of 
both MHC isoforms, which was absent in the HARV and static (Figure 3.7 (b – 
c)). On Day 21, α-MHC upregulation was also significantly higher in perfused 
culture than the other two platforms. MHC markers are an indication of mESC 
differentiation towards cardiomyocytes, and such earlier and higher expressions 
implied the benefits of a perfused and well-mixed environment in enhancing 
cardiomyogenesis of 3D encapsulated mESCs. 





Figure 3-7 Fold changes in expression of cardiac markers (a) cTnT, (b) β-
MHC, and (c) α-MHC during culture period. * represent significant 
difference from previous time point in the same platform. ^ represent 
significant difference from other platforms (or indicated platform) at the same 
time point. ‘s’: static, ‘h’: harv, ‘p’: perfused novel bioreactor. p < 0.05, N = 2 
(a) 
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3.3.4 Higher percentage of cardiac Troponin-I-positive cells in novel 
bioreactor 
The percentages of cardiomyocytes obtained from different culture setups were 
determined by positive expression of cardiac Troponin-I (cTNI) in flow 
cytometry analysis. Similar to cTNT which is used in Section 3.3.3, cTNI is 
involved in calcium signalling central to cardiomyocytes’ contractile motion. 
Figure 3.8 shows that a population with the highest percentage of cardiomyocytes 
is produced in the novel bioreactor on both Day 21 and 25. HARV cultures, on 
the other hand, produced the lowest percentage of differentiated cardiomyocytes. 
Together with the results from cardiac gene expressions, this flow cytometry data 
shows that a continuously perfused environment in the novel bioreactor is 
beneficial for cardiomyogenesis of mESCs. 
 




Figure 3-8 (a) Percentage of cTNI-positive cells as obtained from different 
culture platforms. Bar represents significant difference of indicated sample 
from the non-treated control. p < 0.05, N = 2. (b) Representative flow cytometry 
histograms of fluorescence conjugate-isotype control, and of cTNI-positive cells 
from static, HARV and novel bioreactor cultures after 21 and 25 days.  
(a) 
(b) 
















































- 91 - 
 
3.3.5 Levels of pluripotency in different platforms 
The level of pluripotency in ESCs was monitored with two stem cell markers: 
Nanog and Oct-4 (Figure 3.9). In static culture, Nanog was downregulated (< 1.0 
fold after normalisation to Day 3 static culture) after 16 days while Oct-4 was 
downregulated as early as after 3 days. However, high levels of Nanog and Oct-4 
were consistently expressed in HARV and these expressions were downregulated 
only after 16 days. This downregulation coincided with the upregulation of 
cardiac markers, signifying the loss of pluripotency due to differentiation. 
Meanwhile, in the novel bioreactor, expression profiles of Nanog and Oct-4 did 
not correspond to each other. For instance Nanog expression was significantly 
downregulated at Day 6 while Oct-4 expression increased instead. The increase 
in Oct-4 expression could be explained by some reported results showing that the 
commitment towards cardiac lineage was also accompanied by transient Oct-4 
increase. Oct3/4 binds to and targets genes which participate in mesodermal and 
cardiac lineage specificity and a 2–8 fold increase in Oct3/4 is required for ESCs' 
cardiac differentiation [175]. Furthermore, it was also reported that a large 
percentage of ESCs expressed Oct-4, coupled with Mixl1 after 4 days of 
differentiation [176]. Mixl1 is indicative of primitive streak formation and 
commitment towards mesodermal and endodermal lineages. Thus it can be 
inferred that the Oct-4 upregulation is associated to mesodermal lineage 
commitment instead of pluripotent indication, as observed in the novel 
bioreactor. 
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3.3.6 Higher uniformity of intra-aggregate scaromeric α-actinin 
expression and signalling network in novel bioreactor 
In creating 3D cardiac constructs, the nutrient availability beyond the construct 
peripheral surface is an important consideration; this can be significantly affected 
by hydrodynamic profile and feeding strategy. In this thesis, the impact of 
hydrodynamics on cells in the aggregates' core was evaluated via staining for 
both sacromeric α-actinin and connexin-43 proteins.  
(b) 
(a) 
Figure 3-9 Fold changes in expression of pluripotent markers (a) Nanog, 
and (b) Oct-4 during culture period. * represents significant difference 
from previous time point in the same platform. ^ represents significant 
difference from other platforms (or indicated platform) at the same time 
point. ‘s’: static, ‘h’: harv, ‘p’: perfused bioreactor. p < 0.05, N = 2 
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Scaromeric α-actinin (ATN) is a binding protein that attaches actin filament to 
dense striations in cardiomyocytes. When evaluated against their respective 
nuclei staining, expressions of ATN in static and HARV cultures were localised 
only to the peripheral regions after 21 days (Figure 3.10 (a – b)). In contrast, the 
intra-aggregate expression of ATN in the novel bioreactor culture was more 
uniformly distributed throughout the construct and corresponded to the nucleic 
staining (Figure 3.10 (c)). Uneven distribution of ATN could be due to inferior 
transport of nutrients and oxygen to the aggregates’ cores, limiting differentiation 
ability towards cardiomyocytes.  
Connexins are gap junction proteins that are responsible for intercellular 
signalling through involvement in exchange of small molecules across cell-cell 
interfaces. Thus, they are essential for coordination of cardiomyocyte 
depolarisation. In the atrial and ventricular tissue, connexin-43 is the most 
abundant type of gap junction proteins [177]. Therefore, its network was visually 
analysed through immunostaining of aggregates. Samples from novel bioreactor 
showed uniform fluorescence intensity throughout the cell aggregate, indicating a 
uniform intra-aggregate development of connexin-43 (Figure 3.11). In contrast, 
connexin-43 networks within the aggregates from static and HARV cultures 
showed regions of lower intensity as indicated in Figure 3.11 (a) and (b). These 
regions are beyond the aggregates' peripheral surface. The uneven distribution 
and inferior formation of intra-aggregate connexion-43 networks in static cultures 
could be due to transport limitations into these inner regions. Such transport 
limitations happened as they were primarily driven by diffusion due to absence of 
hydrodynamic profile. Meanwhile, in HARV cultures, sizes of aggregates might 
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have too large, which inhibited efficient transport of nutrients and oxygen into the 






Figure 3-10 Fluorescence micrographs of ATN protein expression 
(green) and nuclei (DAPI-blue) in encapsulated aggregates from (a) 
static, (b) HARV, and (c) perfused bioreactor cultures. Scale bar 












Figure 3-11 Fluorescence micrographs of Connexin-43 networks 
(Rhodamine - red) and nuclei (DAPI - blue) in encapsulated aggregates 
from (a) static, (b) HARV, (c) perfused bioreactor cultures, and (d) 
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3.3.7 Optimisation of aggregates’ size distribution via the novel 
bioreactor’s rotational speed 
As previously described in section 3.3.1, a bimodal aggregate size distribution 
was initially obtained in the novel bioreactor (Figure 3.3 (g)), and such 
distribution was usually not preferred for directed differentiation of ESCs. 
Aggregate distribution with a single and distinct modal size is typically more 
ideal for directed differentiation as it provides better uniformity and control in 
directing ESCs towards the desired lineage. It was hypothesized that improved 
hydrodynamics in the novel bioreactor could improve mESC growth. One 
operational parameter, which could be tuned to alter culture hydrodynamics and 
possibly address the bimodal issue, is the rotary speed of the novel bioreactor. 
When the bioreactor was operated at 10 rpm, it was noticed that the hydrogel 
beads tend to settle at bottom of the rotating vessel. At a faster rotation, a longer 
period of uplifting was achieved and this would enable better mixing of medium 
surrounding the encapsulated cell beads. With improved mixing, supply of 
nutrients among the numerous encapsulated aggregates would be more equally 
distributed. Therefore, when the rotary speed was increased from the initial 10 
rpm to 12.5 rpm, improved cell aggregate profile distribution was achieved. After 
21 days of culture at a rotation speed of 12.5 rpm, size distribution of the mESC 
aggregates improved significantly, giving one distinct modal size (120 – 140 µm) 
and a much smaller size range, as depicted in Figure 3.12. 
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Figure 3-12 Population distribution of aggregates’ sizes after 21 days 
of culture in perfused bioreactor rotating at 10 rpm and 12.5 rpm. 
Legend represents sizes in µm. Binning of 80 – 100 aggregates from 4 
randomly-sampled beads in each rotation speed.  
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3.4 Discussion 
Conventional method of cardiac differentiation of ESCs involves a multi-step 
procedure which makes it laborious for scaling up production of cardiomyocytes. 
This impedes further development of efficient regenerative clinical therapies for 
myocardial infarctions. In this study, encapsulation of mESCs was used to enable 
an integrative single-step cell proliferation and differentiation process in mESC 
culture. Initiating various stages of mESC differentiation was achieved simply by 
changing the medium feed. This minimises the need for the lab operator to handle 
ESCs and conduct EB selection. Eventually, it will reduce contamination risks, 
human errors and improve product reproducibility. 
In numerous studies involving bioreactor cultures, freely suspended aggregates or 
encapsulation in micron-sized hydrogel was used to differentiate mESCs towards 
cardiomyocytes [7, 42, 116, 117, 126]. However, encapsulated mESCs in 
spherical hydrogels were significantly larger. The hydrogel beads used in this 
study were of 2.5 mm in diameter while most studies used microencapsulated 
technologies that produced substrates with sizes ranging from 200–500 μm. 
Larger-sized cardiac constructs are more relevant to tissue engineering and 
clinical therapeutic applications. However, cell culture in such large-sized 
scaffolds can face limitations in nutrient and oxygen transport. Thus utility of 
dynamic and well-mixed culture environment becomes increasingly beneficial 
over static conditions. This comparative study showed the benefits of dynamic 
culture platforms and perfusion for culturing large-sized cardiac constructs. 
Clinically-relevant cell numbers would demand a cell culture platform that 
enables efficient large-scale production, and this is more readily achievable in 
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bioreactors. It was demonstrated that dynamic cultures, i.e. HARV and the novel 
perfused bioreactor, produced an average of 4 x 105 cells per hydrogel bead. 
Considering the number of beads that were used for each platform, this translated 
nearly 2 x 108 cells i.e. a 20-fold increase from initial number of cells seeded. 
This meant that 2 x 108 cells were produced in a vessel volume of 50 mL. In 
contrast, the same volume of static culture produced only 7.5 x 107 cells, which 
translated to a 7.5 fold increase. Besides rotary bioreactors, cultures in stirred 
bioreactor also produced higher cell expansion [7]. These studies clearly 
demonstrated the benefits of dynamic cultures to obtain clinically relevant cell 
numbers. 
Another feature of the novel bioreactor was incorporation of perfusion. In this 
study, cardiomyogenesis in the novel bioreactor was compared to fed-batch 
platforms. Perfusion can ensure a constant supply of soluble factors and removal 
of metabolic by-products, thus achieving environmental consistency during cell 
culture period. The results of this study showed that perfusion was beneficial to 
cardiac differentiation of mESCs. First, the novel bioreactor culture produced 
high cell density with high cell viability and homogeneity. What was more 
distinct to perfusion was the enhanced cardiomyogenesis in the novel bioreactor. 
Though the onset of enhanced cell proliferation was faster in HARV, 
cardiomyogenesis was faster and enhanced in novel bioreactor. Late cardiac 
markers were significantly upregulated in novel bioreactor since Day 16 while 
such upregulation was only later present in HARV and static cultures on Day 21.  
The novel bioreactor also yielded higher percentage of cardiomyocytes than both 
HARV and static cultures. Such improved cardiomyogenesis in perfused 
platforms could also be due to diluting effect of inhibitory factors. Besides this 
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novel bioreactor, which is based on rotary mixing, perfusion could also enhance 
cardiomyogenesis in non-rotary bioreactors, as demonstrated by Niebruegge et al. 
[7]. Perfused stirred bioreactors produced more cardiomyocytes from ESCs than 
their non-perfused counterparts. Another advantage of the perfused feeding 
strategy is improved 3D organisation and uniformity within a 3D cardiac 
construct. In this study, sacromeric α-actinin expression and connexin-43 
network was found to be more uniform within the encapsulated cellular 
aggregates. Perfusion culture onto cardiac construct has been reported coherently 
that they produced cell distribution and contractile properties of higher 
uniformity [94, 111, 112]. These advantages of incorporating a perfused feeding 
strategy could be attributed to (1) a consistent supply of cardiogenic factors 
balanced with a continual removal of inhibitory factors, and (2) the improved 
delivery of soluble factors and oxygen to aggregates’ cores via convective-
diffusive transport. 
One concern was that aggregate size distribution in this novel bioreactor was not 
as uniform as HARV despite its better effects on cardiomyogenesis. It was 
initially hypothesized that a consistent and uniform environment throughout cell 
culture period will enable a more uniform size distribution of the encapsulated 
aggregates. On the contrary, the novel bioreactor gave rise to a bimodal size 
distribution while fed-batch HARV cultures produced the more ideal distribution. 
This implied that operation of this novel bioreactor might require further 
optimisation. Besides the feeding strategy, another distinct difference between 
these two dynamic platforms was the rotary speed. HARV and the novel 
bioreactor were operating at 18–20 rpm and 10 rpm respectively. HARV's higher 
rotary speed enabled the encapsulated cells to be suspended in the vessel's mid 
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region while the encapsulated cells in the novel bioreactor could not achieve this 
state. Rungarunlert et al. found out that the optimal rotary speed for culturing 
embryoid bodies in slow turning lateral vessel (a similar rotary designed vessel) 
was 10 rpm [117]. However, hydrogel beads used in this study might require a 
higher rotating speed. After changing the novel bioreactor's rotary speed to 12.5 
rpm, a better size distribution with one modal size was produced, thereby 
resolving the issue of inferior aggregates' uniformity. 
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3.5 Conclusion 
Choosing the correct cell culture platform is important in 3D cardiac tissue 
engineering and producing cardiomyocytes for clinical therapies. Its 
hydrodynamic profile and feeding strategy will affect availability of nutrients and 
delivery of biochemical cues to the cells. In this study, the feasibility of using the 
novel bioreactor, as previously designed by our laboratory, was demonstrated for 
accelerated cardiomyogenesis of mESCs, so as to produce cardiomyocytes with 
clinically relevant numbers. The dynamic and well-mixed environment in this 
bioreactor could ensure good transport efficacies, which is particularly important 
for larger constructs to maintain cell viability and continued cell growth. 
Improved consistency of environmental parameters due to perfusion also made an 
impact on cardiomyogenesis of mESCs. After establishing such benefits of the 
dynamic and well-mixed environment could have on mESCs, the feasibility of 
using such a system for human pluripotent stem cells could serve a step towards 
translation towards producing cardiomyocytes with clinically relevant numbers.  






4 Sensitivity of ESC 
cardiomyogenesis on 
extracellular pH in 3D bioprocess 
  
As presented in Teo et al (2014), Biochemical Engineering Journal. 90: 8-15 
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4.1 Background 
Utilising cardiomyocytes for clinical therapies require the culture process to be 
defined and cellular products to be well-characterised. In efficient scaled-up 
cultures, ability to control and monitor process variables will be essential to 
achieve reproducible products that can meet the clinical requirements. Perfused 
rotary bioreactors have the benefit of doing so. They are able to allow a well-
mixed environment and a consistent exchange of soluble factors. This feature 
enables culture conditions to be defined and controlled, as compared to fed-batch 
platforms (bioreactors and conventional cultures) where cells will experience 
uncontrolled biochemical and physiological environmental fluctuations, such as 
extracellular pH. 
Amount of hydronium ions in the cellular microenvironment determines its pH. 
These ions participate in numerous biochemical reactions and proteins' structural 
conformation and activities. Hence cellular pathways and cell fates will be 
affected by extracellular pH. Moreover, myocardium is highly sensitive to its 
localised pH variations. For instance pH changes are associated with myocardial 
infarction. In a canine model, the usual myocardial cell pH is 6.94 [178]. 
However, its pH decreases to 6.83 at the onset of infarction and eventually is 
reduced to 6.59. Though this pH change is only 0.35 units, cardiac functionality 
is already compromised, showing the high sensitivity of cardiomyocytes to pH 
changes. Thus creating a controlled environment with monitored levels of 
hydronium ions will be useful in optimising and controlling scaled-up 
cardiomyocytes production.  
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Such high sensitivity of cardiac cells to pH indicates that pH can affect their 
contractile properties. Besides the observation on the in vivo myocardial 
infarction, several studies have also demonstrated that extracellular pH changes 
had an impact on contractile properties in vitro. For instance, cardiomyocytes 
displayed lower contractile forces at pH 6.4 but an increase of pH to higher 
values (between 7.4 and 8.4) would do otherwise [179, 180]. Maintaining 
cultures between pH 7.4 and 7.8 can also increase protein synthesis and prevent 
protein degradation [181, 182]. This may limit myocardial infarction and thus 
benefit clinical therapies. Changes in extracellular pH are observed to affect ion 
exchange channels such as Cl- channels [183, 184]. Human ether-a-go-go related 
gene (hERG) voltage-gated K+ channel is a voltage-insensitive channel and is 
rather difficult to control with conventional ionic gradient. However, Zhou et al. 
has shown its sensitivity to pH changes [185]. With pH's effects on these 
channels, extracellular pH can be a physiological parameter that influences 
cardiomyocytes' contractile properties such as cellular volume and action 
potential. 
Modulation of pH has also been shown to affect the proliferation and 
differentiation activities of stem cells and progenitors [186-189]. One direct 
mechanism is via intracellular pH changes [187, 190, 191]. For instance, as 
extracellular pH varied from 6.7 to 7.3, the intracellular pH in Syrian hamster 
embryo cells changed correspondingly [191]. This intracellular pH change then 
affected cellular mitogen-transduction activities such as tyrosine phosphorylation 
and epidermal-growth-factor induced signalling. Another mechanism of pH 
modulation is through the changes in ion signalling activities [187, 192] caused 
by different levels of H+ ions. One instance was observed in HCO3- channels in 
- 106 - 
 
mouse macrophages [192]. Regardless of mechanism, changes in extracellular pH 
were demonstrated to affect signalling pathways and endogenous production of 
soluble factors that play important roles in cardiomyogenesis of stem cells. Two 
such factors are hypoxia induced factor – 2α (HIF-2α), which affects stem cell 
proliferation and pluripotency [193], and p38 mitogen activated pathway kinase 
(p38 MAPK), a sensitive control for mitogen-activated pathways which regulates 
cardiomyogenesis [194]. 
Studies investigating the effects of extracellular pH on stem cells and progenitors 
are limited. To date, pH ranging around 7.6 was found to be generally more 
beneficial for cell differentiation and maturation than pH 7.1 to 7.4 [188, 189, 
195]. In comparison, optimal pH for cell expansion is not straightforward and is 
more dependent on the cell type. Colonic cells such as HeLa and Chang liver cell 
lines experienced maximum proliferation at pH 8.0 and lower pH levels than 8.0 
would affect their growth adversely. On the other hand, expansion of hemapoetic 
progenitors and embryo cells was preferred in lower pH ranges such as 6.8 to 7.1 
instead [188, 189, 196]. 
Despite the number of studies evaluating pH effects on possible 
cardiomyogenesis has been limited, it is understood that culture pH variation can 
significantly impact differentiation of these cells. Besides determining the 
optimal pH, the cells' sensitivity towards any pH changes must also be 
considered. Inconsistent culture conditions, not uncommon in conventional ESCs 
differentiation protocols, will lead to inter-batch variations of the differentiated 
products [197], undermining efficient production of cardiomyocytes for clinical 
applications. Furthermore, embryo cells are highly sensitive to pH changes. 
Pagano et al. demonstrated an intracellular pH shift of 0.2 units would cause 
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irreversible changes on embryogenesis [198]. Therefore, this section studied 
effects of different pH levels, which were commonly used in ESC 
cardiomyogenesis, to evaluate the pH sensitivity of pluripotent cells during 
cardiac differentiation. 
Manual feeding strategy often produces fluctuations in physiological 
environment and pH values due to the sudden removal of spent medium and 
additional of fresh medium. To achieve conclusive results to determine pH 
sensitivity, extracellular pH conditions should be maintained at the required value 
consistently throughout the culture period. Perfusion enables consistent supply of 
nutrients and removal of metabolites, thus eliminating the need for manual 
medium changes and minimizing physiological fluctuations. With regular 
monitoring, perfusion rate could also be adjusted to address any pH changes due 
to cellular requirements (such as increased respiration and acidosis with higher 
cell numbers). Thus utility of a perfusion system is highly beneficial for 
conducting pH investigation in this study to ensure better homogeneity and 
control of the culture environment. In the previous chapter, the ability of a novel 
rotary, perfused bioreactor to enhance cardiomyogenesis of mESCs was 
demonstrated. This bioreactor can provide a homogeneous and consistent culture 
environment throughout the culture period through its rotary mixing and 
perfusion. Therefore, this bioreactor was used to determine the pH effects on 
cardiomyocytes differentiation of mESCs. 
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4.2 Materials and methods 
4.2.1 mESC maintenance and encapsulation in 3D hydrogel 
mESCs were maintained as described in Section 3.2.1 in mESC maintenance 
medium comprising of high glucose DMEM (Gibco, Lifetech), 10% FBS (gold 
standard, PAA Laboratories), 0.1 mM 2-mercaptoethanol (Sigma), 2 mM L-
glutamine (Gibco, Lifetech), 1x penicillin-streptomycin (PAA Laboratories) and 
1000 U/ml LIF (Millipore, Merck). To initiate cardiomyogenesis in 3D culture 
environment, mESCs were encapsulated using materials and methods as 
described in Section 3.2.3. 
4.2.2 Collection of HepG2-CM 
HepG2-CM was used to condition mESCs towards mesodermal lineage during 
the 3-day expansion stage as illustrated in Figure 4.1. In brief, HepG2 cells were 
routinely cultured in high glucose DMEM (Gibco, Lifetech), 10% FBS (gold 
standard, PAA Laboratories) and 1x penicillin-streptomycin (PAA Laboratories). 
To make the complete HepG2-CM, the medium was collected after 4 days of 
HepG2 culture and prepared as described in Section 3.2.2.   
4.2.3 Cardiomyogenesis of murine ESCs under different pH levels in 
rotary perfused bioreactor  
Murine ESCs were encapsulated in alginate hydrogels at a cell density of 2 x 106 
cells/ml and cultured in the novel rotary perfused bioreactor for investigation of 
their response and sensitivity to different pH levels that were commonly used in 
cell cultures. Differentiation protocol was adopted from previous section (Section 
3.2.4) and illustrated in Figure 4.1. After 3 days of using HepG2-CM medium 
feed for mESC expansion and mesodermal-conditioning, the feed was changed to 
differentiating medium of the various pH values (pH 6.8, 7.1 and 7.4). 
Differentiating medium consisted of high glucose IMDM, 20% FBS (gold 
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standard, PAA Laboratories), 450 µM 1-thioglycerol (Sigma-Aldrich), 2 mM L-
glutamine (Gibco, Lifetech), 1x penicillin-streptomycin (PAA Laboratories) and 
0.25 µM Cardiogenol C (Sigma-Aldrich). The basal IMDM medium used was 
reconstituted from powder (Gibco, Lifetech) and did not contain any sodium 
bicarbonate. Different amounts of sodium bicarbonate were added to achieve the 
required pH values in final differentiating medium. 1.0 g/L, 3.0 g/L and 4.8 g/L 
of sodium bicarbonate (Sigma) were first added to the reconstituted IMDM basal 
medium. After supplementing with other components, the final medium had 
sodium bicarbonate concentrations of 0.8 g/L, 2.4 g/L and 3.84 g/L. When 
equilibrated with 5% carbon dioxide in humidifier incubator, they produced 
environments with pH 6.8, 7.1 and 7.4 respectively. During differentiation, 50 
mL medium was perfused daily to achieve a continuous exchange of nutrients 
and metabolites.  





Figure 4-1 (a) Schematic diagram of procedure in encapsulation and 
culture of mESCs in perfused bioreactor for studying pH effects on 
cardiomyogenesis. (b) Timeline of medium introduction into perfused 
bioreactor. HepG2-CM was used for initial three days of cell expansion 
and conditioning towards mesodermal lineage. Thereafter 
differentiating medium of various pH values was used. 
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4.2.4 Maintenance of culture pH in bioreactor setup 
Continuous rotation of the novel bioreactor enables a dynamic culture 
environment that ensured homogeneous distribution of nutrients. It was 
demonstrated that more rapid and efficient transport of nutrients was achieved 
throughout the culture vessel and in alginate beads for perfused bioreactor 
compared to that in conventional static cultures [170, 199]. As there was 
negligible diffusion limitations in alginate hydrogel in the perfused bioreactor 
[199], a uniform pH environment was assumed to be maintained through the bulk 
medium and in the encapsulated cells.  
The extracellular pH was then monitored throughout the differentiation process 
via sampling every two days by sampling the spent medium collected in waste 
bottle and also by sampling medium in culture vessel during every sample 
collection point (i.e. Day 6, 10, 16 and 21 of culture). During each time point,  
two samples were withdrawn from each set up and measurements were taken 
with a pH meter (Ezdo PL600, Gondo Electronic Co. Ltd.). With a daily 
perfusion rate of one bioreactor vessel volume (50 ml/day), the culture pH values 
(from Day 3 to end of culture) were maintained at 6.80 ± 0.02, 7.11 ± 0.03 and 
7.38 ± 0.03 respectively. Therefore, the perfused bioreactor was able to ensure a 
tight control of pH over a long-term culture, which made it possible to study the 
effects of pH on cardiac differentiation of mESCs. 
4.2.5 Microscopic visualisation and live/dead staining 
Cell proliferation was observed with an inverted optical microscope (Axiovert 
200M, Zeiss) and images were captured with its accompanying camera 
(AxioCam MRc, Zeiss). Cell viability of encapsulated cell aggregates were 
assessed by incubation with 2 µM of calcein-AM (Sigma) and 4 µM of 
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propidium iodide (Sigma-Aldrich) for 30 mins at 37oC in the dark. Thereafter, the 
encapsulated cells were washed with PBS twice to remove any residual dye. 
Their overall viability was evaluated qualitatively with fluorescence images that 
were captured by inverted fluorescence microscope (Axiovert 200M, Zeiss) and 
camera (AxioCam MRc, Zeiss).  
4.2.6 Cell proliferation assay 
Cell proliferation under different pH environment was also compared 
quantitatively with tetrazolium salt, WST-8* (Cell Counting Kit 8, Dojindo). 
WST-8* will be reduced to yellow formazon by cellular dehydrogenase activities. 
Measurement of the yellow absorbance will be indicative of cellular 
dehydrogenase activities and thus cell numbers and proliferation.  
To measure for cell proliferation activities, five beads were sampled for every 
experimental setup. Each bead was first placed into an individual 96-well and 
washed twice with PBS. Thereafter, they were each incubated with 100 µl of 
fresh medium and 10 µl of WST-8* reagent in 37oC, 5% CO2 incubator for two 
hours. Meanwhile, 100 µl fresh medium was also incubated with 10 µl WST-8* 
to serve as blank samples. After incubation, 100 µl of reacted solution from the 
blank controls and samples were transferred to a new 96-well. They were finally 
measured for the yellow absorbance of formazon at 450 nm in microplate 
spectrophotometer (Bio-rad).  
4.2.7 Quantitative PCR 
Total RNA was extracted from collected cell pellets using RNeasy kit (Qiagen) 
according to manufacturer's instructions. Extracted RNA was then quantified 
with a UV spectrophotometer (Evolution 500, Thermo). To synthesize the first 
strand of cDNA from 1 µg RNA, M-MLV reverse transcriptase, oligo-dT 
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primers, dNTP mix and RNasin were used according to manufacturer's 
instructions (all reagents from Promega). The final volume was made up to 25 µl 
with nuclease-free water (Microbiology grade, Hyclone). 
For comparison of cardiomyogenesis and differentiation under different pH 
environments, various gene expressions (as seen in Table 4.1) were quantified via 
quantitative PCR after ensuring that all primers have similar amplification 
efficiencies. Target genes were amplified and quantified with SensiFASTTM 
SYBR Green Fluorescein kit (Bioline). 100 ng cDNA was mixed with 10 µl 
mastermix and 400 mM primers (1st Base Asia, Table 4.1), and nuclease-free 
water was added to make a final volume of 20 µl. The samples then underwent 
PCR amplification and measurement in iQ5 (Bio-rad). A typical PCR 
amplification protocol involved an initial step of 2 mins denaturation at 95oC and 
amplification stage of 40 cycles of 10 secs denaturation at 95oC and 30 secs 
annealing/extension at 60oC. PCR end products were analysed with 
electrophoresis in 2% agarose gel and ethidium bromide to ensure the absence of 
any side products and formation of primer-dimers. A melt curve were also 
conducted after every PCR run to ensure the specificity of amplification to the 
target gene. PCR data was normalised to the pH 7.1 samples on Day 3, which 
corresponded to the introduction of different pH environments, and fold changes 
were calculated with 2-∆∆CT method, as described in Section 3.2.9. 
4.2.8 Flow cytometry 
To investigate the effects of pH on the amount of mESCs differentiating to 
cardiomyocytes, flow cytometry was used to determine the percentage of cells 
positive for expression of two cardiac proteins, namely cardiac troponin-I and 
sacromeric α-actinin.  
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First, cells were extracted from the alginate hydrogel as described in Section 
3.2.5 and the extracted cells were treated in preparation for antibody incubation 
as described in Section 3.2.10. The cells were then incubated with 2 µl of each 
primary antibody shown in Table 4.2 for two hours at 4oC. Next, the cells were 
washed twice with cold PBS and incubated with 100 µl of secondary antibodies 
(Table 4.2) for another one hour at room temperature in the dark. To remove any 
residual antibodies, the cells were washed twice with cold PBS. Finally, the cells 
were re-suspended in PBS consisting of 2% paraformaldehyde, 3% bovine serum 
albumin and 1% sodium azide, and were kept in 4oC for storage up to one week. 
Finally, these stained cells were processed in flow cytometer (FACSCalibur, BD 
Biosciences) and analysed in flow cytometry software FlowJo (Tree Star). 
Table 4-1 List of studied genes and their respective primers in studying 
effects of pH environments on cardiomyogenesis 
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Table 4-2 List of antibodies used in flow cytometry  
Primary antibody Corresponding secondary antibody
Cardiac Troponin I Goat anti-rabbit IgG-FITC
(H-41, Santa Cruz Biotechnology) (400x dilution, Abcam)
Sacromeric α-actinin Goat anti-mouse IgG1-PerCP
(EA-53, Santa Cruz Biotechnology) (100x dilution, Santa Cruz Biotechnology) 
 
4.2.9 Immunocytochemistry 
Encapsulated cells cultured under different pH environments were fixed and 
processed for immunostaining as described in Section 3.2.10. For 
immunostaining, the sectioned samples were first incubated with 10% goat serum 
for 30 mins at room temperature to block out non-specific binding. They were 
then incubated with sacromeric α-actinin (EA-53, Santa Cruz Biotechnologies, 
100x dilution in primary diluents of 0.1% sodium azide and 1% bovine serum 
albumin in PBS) and SSEA-1 (MC-480, Santa Cruz Biotechnologies, 100x 
dilution) primary antibodies at 4oC for two hours. Thereafter, the slides were 
washed with PBS thrice and incubated with FITC-conjugated and TRITC-
conjugated secondary antibodies respectively (100x dilution in 1% bovine serum 
albumin in PBS) at room temperature in the dark. After incubation the slides 
were washed on a shaker for 10 mins thrice to remove any residual unbound 
antibodies. Finally, the samples were incubated with DAPI dye for 5 – 10 mins 
for nuclei-staining and imaged under a fluorescence microscope (Axiovert 200M, 
Zeiss) and camera (AxioCam MRc, Zeiss). 
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4.2.10 Statistical analysis 
All statistical analysis was conducted by using Microsoft Office Excel analysis 
tool package (Excel 2013, Microsoft). After verifying with F-test that there were 
unequal variances in the different data sets, student t-test with unequal variances 
were used. This was used to test for inter-group differences of 95% significance 
in cell proliferation data, quantitative PCR data, and flow cytometry data. Error 
bars on the charts were representative of the standard deviations. The sample 
populations (N) are indicated in the legends of the respective figures and 
represent the total number of biological replicates from two independent 
experimental runs.  
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4.3 Results 
4.3.1 ESCs’ proliferation and viability under different pH 
environments 
Cell growth of the encapsulated mESCs in different pH environments were 
monitored under the microscope. Figures 4.2 showed aggregate densities under 
various pH values at Day 10 and 21. At Day 10 (Figure 4.2 (a – c)), the 
aggregates at pH 6.8 were slightly more sparsely packed and smaller than those at 
pH 7.1 and 7.4. By Day 21 (Figure 4.2 (d – f)), these differences were more 
attenuated. Similar observations throughout the whole differentiation period 
suggested that aggregates cultured at pH 6.8 were not as dense as those at pH 7.1 
and 7.4 and indicated that a slight increase in acidity could cause lower cell 
number and proliferation.  
Proliferation assay also showed similar trends as indicated by these microscopic 
observations (Figure 4.3). Throughout the entire differentiation period, cell 
expansion was the lowest at pH 6.8, giving 2.8-fold increase after 21 days. 
Meanwhile, cell culture at pH 7.4 produced the highest expansion fold of 3.4 
folds after 21 days, which was 10% and 21% more than that at pH 7.1 and 6.8 
respectively. Different pH environments also affected the onset of exponential 
growth during proliferation. For instance at pH 7.1 and 7.4, the exponential 
growth started before Day 3. However, this was only observed at pH 6.8 on Day 
6, indicating a longer lag phase induced by acidic environment.  
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Figure 4-3 Cell proliferation profiles under different pH environments. 
Expansion fold of respective point is obtained by normalising its assay 
absorbance to that on Day 3. Unless indicated, * represents significant 
differences from the other two pH environments at each respective time 
point. p < 0.01., N = 10 from two independent runs 












Figure 4-2 Photomicrographs of encapsulated aggregates in alginate 
hydrogel after (a-c) 10 days, and (d-f) 21 days of culture. Scale bar 






pH 7.1 pH 7.4 
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Another effect of pH on cellular expansion is cell viability. From the fluorescence 
micrographs of live/dead staining after 21 days of culture (Figure 4.4), the 
highest percentage of dead cells was observed at pH 6.8. These dead cells were 
most probably caused by exposure to unfavourable extracellular conditions such 
as higher amount of hydronium ions at lower pH. The nutrients transport 
limitations as a probable cause was ruled out because cell viabilities were not 
compromised in cultures at pH 7.1 and 7.4 and these regions of dead cells were 
mostly concentrated along the periphery of cell aggregates, which did not face 
limited nutrient supply. 
 
4.3.2 Cardiomyocyte differentiation and sensitivity towards pH 
environment 
Effects of pH on directed differentiation of mESCs towards cardiomyocytes was 
evaluated by comparing cardiac gene expressions of cells cultured at different pH 
Figure 4-4 Live/dead fluorescence 
images of encapsulated 
aggregates on Day 21 at (a) pH 
6.8, (b) pH 7.1, and (c) pH 7.4. 
Green and red fluorescence 
represent live and dead cells 
respectively.  Scale bar represents 
100 µm. 
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levels. Gene expressions of all samples were normalised to those expressed at 
Day 3 of culture, which corresponded to the start of directed differentiation. 
Upon comparing various cardiac gene levels expressed at different pH values, it 
showed that the genes were more upregulated at pH 7.1 and 7.4 than at pH 6.8 by 
Day 21. For instance on Day 21, mesodermal marker Brachyury T and cardiac 
progenitor marker Nkx-2.5 had the lowest expression levels at pH 6.8 while no 
significant difference was observed for cultures at pH 7.1 and 7.4 (Figure 4.5).  
Late cardiac markers also showed similar trends as those for Brachyury T and 
Nkx-2.5. Gene expressions for structural motor proteins α- and β-MHC and 
regulatory calcium-signalling protein cTNT were higher at pH 7.1 and 7.4 than at 
pH 6.8. On Day 21, expression of α-MHC in cells cultured at pH 6.8 gave around 
20 fold increase while that at pH 7.1 and 7.4 ranged around 1000 – 1500 fold 
(Figure 4.6 (a)). This showed that the slight decrease in pH could cause a 
significant reduction in α-MHC expression. Expression of β-MHC was also 
lower at pH 6.8 (Figure 4.6 (b)). On Day 16, expression of β-MHC was 
upregulated by 11 folds at pH 6.8 while cells experienced an 100-fold 
upregulation at pH 7.1 and 7.4. The difference of such extent persisted till Day 
21, where cells produced about 40 and 400 folds upregulation of β-MHC at pH 
6.8 and the other two higher pH environments respectively. Meanwhile, in Figure 
4.6 (c), cTNT expression was initially highest at pH 6.8 on Day 16. However, this 
upregulation stagnated at around 50-fold increase for the last 5 days of 
differentiation. In contrast, cells at pH 7.1 and 7.4 produced an exponentially 
increase in cTNT expression of about 1000 – 1500 folds, which corresponded to 
the increase in α- and β-MHC expression. Observations from these various 
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cardiac markers showed the significant reduction of mESCs’ cardiomyogenesis 





Figure 4-5 Fold changes in gene expression of (a) mesodermal marker 
Brachyury T, and (b) early cardiac progenitor marker Nkx2.-5 on 
respective days of differentiation process. * represent significant 
difference from the previous time point under same pH condition. 
Indicated bars represent significant differences from other pH conditions 
at the same time point. p < 0.05, N = 2 




Figure 4-6 Fold changes in gene expression of late cardiac markers (a) 
α-MHC, (b) β-MHC, and (c) cTNT on respective days of 
differentiation process. * represent significant difference from the 
previous time point under same pH condition. Indicated bars 
represent significant differences from other pH conditions at the same 
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Percentages of cells differentiating to cardiomyocytes under different pH 
environments were also evaluated by flow cytometry for sacromeric α-actinin 
(ATN) and cardiac troponin I (cTNI). α-actinin is a cytoskeleton protein and 
includes α- and β-spectrins and dystrophins. Sacromeric α-actinin (ATN) is found 
in the Z-disc and dense striations in cardiomyocytes, anchoring the actin filament 
and taking part in the contractile motion of cardiomyocytes. Meanwhile, cTNI is 
a sub-unit of cardiac troponin, which participates in calcium signalling for 
cardiomyocytes’ contractile motion. From gene expression data, the significant 
observation is the reduced cardiac gene expressions at pH 6.8 as compared to pH 
7.1 and 7.4. Since there was no significant difference between the cardiac genes 
at pH 7.1 and 7.4, only samples from pH 6.8 and 7.1 were used to investigate the 
effects of reduced pH on the cardiomyocyte yield.    
From the flow cytometry analysis (Table 4.3 and Figure 7.4), a slight pH 
decrease to pH 6.8 lowered the percentage of cells positive for cTNI and ATN 
expressions, indicating reduced cell yields in differentiated cardiomyocytes. At 
Day 21, there were 20.6% of cTNI-positive cells under pH 7.1 while only 10.3% 
of cells were positive for cTNI under pH 6.8 conditions. The expressions of these 
cardiac proteins correlate to the cardiac gene expressions and indicate an 
inhibition effect in cardiomyogenesis by slight pH decrease. 
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Table 4-3 Comparison of cTNI-positive and ATN-positive cells evaluated by 
flow cytometry for pH 6.8 and 7.1 at Day 21 and Day 25. * represents 
significant difference of respective samples on the same day. p<0.05, N=2 
D21 D25 D21 D25
pH 6.8 10.3 ± 1.4 (*) 23.6 ± 0.8 (*) 10.4 ± 0.8 16.4 ± 0.8 (*)






Figure 4-7 Representative flow cytometry histograms of cTNI- and 
ATN-positive cells in isotype control and cells differentiatied at pH 
6.8 and 7.1 on Day 25. 
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4.3.3 Sacromeric α-actinin network under different pH environments 
Sacromeric α-actinin (ATN) networks within encapsulated cell aggregates were 
visualised via immunocytochemistry to compare the extent and uniformity of 
sacromeric networks formed in differentiated cardiomyocytes. At pH 6.8, the 
aggregates produced non-uniform distribution of cardiomyocyte differentiation; 
areas which displayed strong ATN expression were along the cellular aggregates’ 
peripheral regions while the inner cores were absent of ATN (Figure 4.8 (a)). On 
the other hand, Figures 4.8 (b) and (c) showed a more uniform expression for 
areas that were positive for ATN in aggregates from pH 7.1 and 7.4. 
 
Figure 4-8 Fluorescence micrographs 
of ATN expression (FITC - green) 
and nuclei (DAPI-blue) in 
encapsulated aggregates from pH (a) 
6.8, (b) 7.1, and (c) 7.4 cultures. The 
colour of cyan represents an overlap 
of FITC and DAPI. Scale bar 
represents 50 μm 
(c) 
(a) (b) 
DAPI FITC DAPI FITC 
DAPI FITC 
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4.3.4 Effects of pH on residual ESC pluripotency  
Besides investigating expressions of cardiac genes, pluripotency and 
differentiation towards endodermal and ectodermal lineages was also briefly 
monitored. Residual pluripotency of ESCs was a major issue in its utility for 
clinical application. Undifferentiated ESCs can cause tetratomas when 
transplanted, causing highly detrimental effects to the patient. Thus, pluripotency 
levels of mESCs differentiated at these different pH environments was 
investigated by studying the gene expression of pluripotency markers, Nanog and 
Oct-4.  
Expression of Nanog (Figure 4.9 (a)) was significantly higher at pH 6.8 than at 
pH 7.1 and 7.4 since Day 16. During the last five days of differentiation at pH 7.1 
and 7.4, its expression decreased to levels lower than 0.5-fold, indicating a 
downregulation and loss of pluripotency. This is a strong correlation to the 
significant increases in cardiac gene expressions, showing directed differentiation 
of ESCs towards cardiomyocytes. However, cells at pH 6.8 experienced an 
upregulation of Nanog, giving a 3.4-fold increase. Such contrast between cells at 
pH 6.8 and at the other two pH environments was also observed for Oct-4 
expression (Figure 4.9 (b)). At Day 21, Oct-4 was down-regulated at pH 7.1 and 
7.4 while it showed an upregulation at pH 6.8.  
Stage-specific embryonic antigen 1 (SSEA-1) protein expressions were also 
evaluated via immunostaining to determine the extent of residual pluripotency in 
the different pH environments. SSEA-1 plays an important part in adhesion and 
migration of the cells in the preimplantation embryo and is a marker of 
undifferentiated mESCs. Similar to the Nanog and Oct-4 gene expressions, 
SSEA-1 protein expressions on Day 21 were much higher at pH 6.8 than pH 7.1 
- 127 - 
 
and 7.4 (Figure 4.10). At pH 6.8, aggregates showed a high presence of SSEA-1 
proteins while those at pH 7.1 and 7.4 showed lower levels and scattered regions 
of SSEA-1 expressions. Results of the pluripotent gene expressions and protein 
expression showed that ESC maintained a higher level of residual pluripotency at 




Figure 4-9 Fold changes in gene expression of pluripotent markers (a) 
Nanog and (b) Oct-4 on respective days of differentiation process. * 
represent significant difference from the previous time point under 
same pH condition. Indicated bars represent significant differences 
from other pH conditions at the same time point. p < 0.05, N = 2 
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4.3.5 Effects of pH on spontaneous endodermal and ectodermal 
differentiation of ESCs 
Undesired ESC differentiation towards endodermal and ectodermal lineages was 
briefly evaluated with α-fetoprotein (AFP) and nestin markers respectively. For 
AFP, no significant difference between the different pH environments was 
observed (Figure 4.11 (a)). This implies that endodermal differentiation was not 
as sensitive as cardiomyogenesis of mESCs at this tested pH range. Meanwhile, 
nestin expression levels showed otherwise, as seen in Figure 4.11 (b). At Day 21, 
it showed a higher gene expression at pH 7.1 than pH 6.8 and 7.4. Expressions of 
(c) 
(a) (b) 
Figure 4-10 Fluorescence 
micrographs of SSEA-1 expression 
(TRITC-red) and nuclei (DAPI-
blue) in encapsulated aggregates 
from pH (a) 6.8, (b) 7.1, and (c) 7.4 
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all cardiac and pluripotent markers had produced similar levels at pH 7.1 and 7.4 
but nestin was the only exception. This indicates that within the tested pH range 
of 6.8 to 7.4, ectodermal differentiation of mESCs will be quite sensitive to any 
slight pH changes, thus affecting the efficacy of producing cardiomyocytes for 






Figure 4-11 Fold changes in gene expression of (a) early endodermal 
marker AFP, and (b) early ectodermal marker Nestin on respective 
days of differentiation process. * represent significant difference from 
the previous time point under same pH condition. Indicated bars 
represent significant differences from other pH conditions at the same 
time point. p < 0.05, N = 2 
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4.3.6 Expression of signalling proteins, HIF-2α and MAPK14 
Two important signalling pathways that could link to the differences observed in 
mESC pluripotency and cardiomyogenesis were studied. HIF-2α expression was 
found to be significantly higher at pH 6.8 than at pH 7.1 and 7.4 (Figure 4.12 (a)).  
Meanwhile, expression of p38 MAPK was studied via its isoform MAPK14 
(Figure 4.12 (b)). It was also shown that expression of MAPK14 was highest at 
pH 6.8 and the lowest at pH 7.4. Significant differences in expression levels of 





Figure 4-12 Fold changes in gene expressions of (a) HIF-2α, and (b) 
MAPK14 on respective days of differentiation process. * represent 
significant difference from the previous time point under same pH 
condition. Indicated bars represent significant differences from other 
pH conditions at the same time point. p < 0.05, N = 2 
- 131 - 
 
4.4 Discussion 
Physiological environment is an important consideration in maximising 
cardiomyocyte yields. One such physiological parameter that could affect cell 
fate is the pH environment of cell culture. However, maintaining pH at a 
consistent value is often difficult in conventional flask cultures due to localised 
and perhaps rapid accumulation of metabolites, especially in high cell density 
cultures. Hence, investigation of pH effects on cardiomyogenesis in flask cultures 
will face challenges to obtain conclusive results. The rotary perfused bioreactor, 
on the other hand, is able to maintain an environment at a consistent pH value 
throughout cardiomyogenesis and therefore a suitable culture platform to study 
pH sensitivity. Furthermore, an optimal pH condition was believed to be 
necessary to maximise yields and homogeneity of cell output in the 3D cell 
culture bioprocess for pluripotent cells.  
This chapter compared cardiomyogenesis under three pH environments which 
were commonly found in ex vivo studies: pH 6.8, 7.1 and 7.4. The tight pH range 
was chosen to simulate a study of the dependence and sensitivity of ESCs toward 
cardiomyogenesis under small variable changes in pH conditions. Under manual 
feeding such as in standard flask cultures, cells may suffer from an accumulation 
of metabolites which often gives rise to slightly acidic environment dropping to 
around pH 6.8. Such pH condition has also been observed commonly in damaged 
tissues as those found at the onset of myocardial infarction. Environments with 
pH 7.1 and 7.4 were chosen as they are common in the preparation of fresh cell 
culture medium. Moreover, pH 7.4 is found in peripheral blood of human body, 
thus it is also the usual standard pH recommended for cell culture. By studying 
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these three pH conditions and using mESCs as the pluripotent cell model, this 
study demonstrated the importance of pH control in 3D bioprocess.  
Under conditions similar to damaged tissues, such as a slightly acidic 
environment of pH 6.8, stem cells like mesenchymal stem cells experienced 
growth inhibition and lower viabilities [200]. The pH value during fetus 
development ranges 7.0 to 7.5 due to the amniotic fluid environment. Therefore, 
a shift in pH from this range may affect both embryonic development and ex vivo 
cultures of ESCs. It was demonstrated in this chapter that a slight drop in pH to 
6.8 resulted in compromised mESC proliferation and viability during 
cardiomyogenesis while pH 7.4 produced the highest number of cells. Using 
cardiomyocytes for tissue engineering and regenerative therapies faces a 
challenge of obtaining clinically relevant numbers efficiently. From these 
comparisons of cell numbers and viabilities at different pH environments, it was 
shown that pH plays a significant role in determining the bioprocess efficiency in 
producing required cell numbers. 
The extent of cardiomyocyte differentiation and residual pluripotency of mESCs 
were also affected by slight variations in pH environments. A slight change to an 
acidic environment of pH 6.8 resulted in decreased cardiomyogenesis, as 
indicated by both lower cardiac gene expressions and percentage of ATN-
positive and cTNI-positive cells. This could be attributed to changes in signalling 
pathway. Hydronium ions can influence protein conformation, thus affecting 
protein binding and signalling. Through studying the pH effects on signalling 
proteins, one could not only gain insight on impact on cardiomyogenesis but also 
on other possible cell fates where the studied signalling protein participated in. 
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MAPK signalling is one major pathway involved in cardiomyogenesis, and was 
studied to determine any possible effects due to the different pH environments.  
MAPK signalling plays an important role in ESC differentiation and it depends 
on interplay of three major pathways: (1) c-Jun NH2-terminal kinases, (2) 
extracellular signal-regulated kinases, and (3) p38 MAPK. The first two 
pathways were shown to be required for cardiomyogenesis, where their inhibition 
would result in any upregulation of cardiac markers to cease [201].  Meanwhile, 
studies showed the complexity of p38 MAPK’s effect on cardiomyogenesis, 
indicating that different stages of cardiomyogenesis might be more sensitive to 
p38 MAPK signalling. For instance, p38 MAPK was found to be essential for 
ESC commitment towards mesodermal lineage and cardiomyocyte differentiation 
[202]. However, inhibiting p38 MAPK signalling could enhance cardiomyocyte 
differentiation of ESCs [203, 204]. It was demonstrated that after 21 days, lower 
levels of p38 MAPK gene were expressed in cells cultured at pH 7.1 and 7.4, 
which corresponded to the increased cardiac markers. This implied that changes 
in hydronium ions concentration might have affected extent of mESC 
cardiomyogenesis via p38 MAPK signalling. p38 MAPK signalling is also 
involved in regulating mESC commitment towards neuronal cells, thus acting as 
a control between cardiomyogenesis and neural commitment [205]. Herein, 
different p38 MAPK expression levels were observed at pH 7.1 and 7.4, which 
may be an explanation for the higher level of spontaneous ectodermal 
differentiation at pH 7.1. These results showed that p38 MAPK signalling 
pathway involved in cardiomyogenesis is very sensitive to pH changes. 
Furthermore, there are other pathways partaking roles in differentiation towards 
other lineages which may be sensitive to pH changes and were not studied in this 
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chapter. Thus controlling pH in bioprocess can help to increase cardiomyocyte 
yield and purity from pluripotent sources. 
Besides considering the level of cardiomyocyte differentiation, residual 
pluripotency of ESCs must also be considered in lieu of risk in forming 
teratomas. A slight decrease of pH to 6.8 caused higher residual pluripotency, 
even after 21 days of differentiation. A pH study on glioma stem cells [193] also 
showed that their stemness increased in environments with low pH. Such effect 
was attributed to induction of hypoxia-induced factor (HIF-2α). ESCs will 
experience upregulation of HIF-2α when subjected to stressful environment, and 
this will then enhance their pluripotent phenotype [206]. As demonstrated here, 
the higher pluripotency levels of cells at pH 6.8 was accompanied with higher 
expression of HIF-2α. This agreed with Hjelmeland et al. and Das et al. [193, 
206], illustrating the effects of pH on residual pluripotency via HIF-2α signalling. 
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4.5 Conclusion 
There was a significant impact on cell proliferation, viabilities and differentiation 
of ESCs even within the narrow range of the pH environments studied here. In 
general, a slight drop of pH to acidic environment of pH 6.8 resulted in 
compromised proliferation, viability and lower cardiomyocytes yield of mESCs. 
Furthermore, this slight pH change also resulted in higher residual pluripotency. 
Such differences were attributed to the changes in signalling pathways, such as 
level of p38 MAPK and HIF-2α expressions. From this study, cardiomyogeneis 
of mESCs were proven to be highly sensitive to the pH environment. Similarly, 
human pluripotent cells may also display sensitivities to pH environment during 
cardiac differentiation. Therefore, in the utility of human pluripotent cells for 
producing for clinical applications, pH environment should also be studied with 
great importance. The sensitivity of pluripotent cells towards pH demonstrates 
that a stringent pH control is important in 3D bioprocess to ensure a more 
efficient production of cardiomyocytes for tissue engineering and regenerative 
clinical applications.   






5 Ultrasound as mechanical 
stimulation for cardiomyogenesis 
of ESCs 
  
As presented in a manuscript for Plos ONE 
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5.1 Background 
Mechanical stimulation has been used extensively to enhance cardiomyocyte 
differentiation and maturation for tissue engineering applications, as mentioned 
in Section 2.5.1. Ultrasound is a possible form of stimulation which can be 
incorporated into stem cell bioprocessing to produce cardiomyocytes for clinical 
purposes.  
Ultrasound is a longitudinal wave, i.e. particles are displaced along the direction 
of wave propagation. Ultrasound source will produce a vibratory motion and 
result in compression and rarefaction of particles displacement. Therefore, 
subjecting cells to ultrasound will expose these cells to repeated and rapid 
vibratory particulate movements. This can have possible influence on cell fate 
through mechanotransduction and mechanical cues, as demonstrated in 
mechanical stimulation studies introducing shear stress or physical stretching on 
cardiac constructs [8, 10, 147, 156]. Intensity of ultrasound in diagnostic and 
therapeutic applications can be as high as 300 W/cm2. However, using ultrasound 
of such high intensity will face problems of generating heat that causes 
detrimental effects to the treated cells, especially in ex vivo cultures where cells 
are highly exposed to any physiological stimuli. To alleviate this problem, low 
intensity ultrasound (LIUS) has been developed. LIUS has an intensity of lower 
than 1 W/cm2, and is already utilised in biomedical applications like diagnostic 
imaging and bone fracture healing. The heat generated from LIUS is minimal and 
will not have any thermal nor destructive effects. Therefore, LIUS can be safely 
used as a mechanical stimulus and has great potential as a tool in producing cells 
for regenerative and clinical therapies.  
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LIUS has been shown to affect growth and differentiation of stem cells and 
progenitors for the production of various mature cells in tissue engineering and 
regenerative therapies. For instance, human MSCs exhibited higher proliferation 
and viabilities when subjected to LIUS [207, 208]. Effects of LIUS on 
osteogenesis and chondrogenesis of different cell sources have been extensively 
studied in vivo and in vitro. In a study by Cheung et al. [209], MSCs were first 
transplanted into bone fracture regions in rat models and these regions were 
treated with LIUS. The treated rats then experienced enhanced bone healing. 
Such benefits of LIUS ability to enhance directed differentiation towards 
osteogenic lineages were also demonstrated in ex vivo cell cultures. Studies 
showed LIUS treatments to increase osteoblastic gene expressions in 
differentiating adipose stem cells, myoblasts and hematoma progenitor cells 
[210-212]. Similarly, chondrogenesis was also enhanced by LIUS for cartilage 
tissue engineering and regeneration. LIUS treatments gave rise to higher 
chondrogenic gene expression, higher amounts of collagen and 
glycosaminoglycan, and better mechanical properties (i.e. higher similarity to in 
vivo cartilage) in differentiating MSCs [213-216]. LIUS can benefit both 
osteogenesis and chondrogenesis, thus allowing competition for lineage 
commitment of multipotent/pluripotent sources, hence reducing efficient 
production of required cells. To prevent this and enable efficient directed 
differentiation, chemical cues can be added to direct differentiation towards the 
intended lineage while using LIUS as a complementary and synergistic 
mechanical stimulus [217, 218]. 
Studies investigating effects of LIUS on cell differentiation were mostly in bone 
and cartilage regeneration. In contrast, such works on cardiac regeneration has 
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been very limited. A study related to this field was conducted by Park et al. [219]. 
In their study, they showed LIUS's ability to enhance myoblast differentiation 
towards matured myosin lineage. They subjected myoblasts to 10 mins of 30 
mW/cm2 LIUS daily. After six days, tropomyosin was present in the treated 
myoblasts and not in the untreated controls. This signifies that LIUS can provide 
mechanical cues which can enhance differentiation towards a myocyte lineage. 
Another evidence that suggested LIUS candidacy as a mechanical stimuli for 
cardiac regeneration is expression of angiotensin II Type 1 (AT1) receptors in 
osteoblasts. When osteoblasts underwent LIUS treatments, they produced an 
unregulated AT1 receptor expression [220]. AT1 receptor is a mechanoreceptor 
commonly found in cardiomyocytes, thus this enhancement displayed in 
osteoblasts may be also be possible in cell sources for cardiac regeneration. 
These studies of LIUS effects on tissue engineering and regenerative therapies 
show the great potential of using LIUS to enhance cardiomyocytes differentiation 
and maturation. It was hypothesised that LIUS can serve to enhance cardiac 
differentiation of pluripotent cell sources in a cardiogenic environment via its 
mechanical cues. In this chapter, effects of LIUS on cardiomyocyte 
differentiation of mESCs were investigated in both 2D and 3D culture platforms. 
The primary motivation here is to show the feasibility of using ultrasound to 
enhance the cardiomyogenic environment of pluripotent stem cells by first 
demonstrating it on murine embryonic stem cells. The cells were subjected to 
daily treatment of LIUS for 10 mins at different intensities (30 and 300 mW/cm2) 
and wave generation mode (continuous and pulsed wave). After 3 weeks of 
differentiation, cells were then evaluated for their viability and the various 
cardiac markers.   
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5.2 Materials and methods 
5.2.1 Murine ESCs maintenance and HepG2-CM collection 
mESCs (E14Tg2a, ATCC) were cultured and maintained as described in Section 
3.2.1 prior to differentiation. Meanwhile, HepG2 cells were also cultured and 
HepG2-CM was prepared as described in Section 3.2.2. 
5.2.2 Cardiac differentiation and ultrasound stimulation of mESCs in 
2D culture 
Prior to directed cardiac differentiation, mESCs were cultured in HepG2-CM and 
on TCP coated with 0.1% porcine gelatin (Sigma) for 3 days for conditioning 
towards mesodermal commitment. To initiate cardiac differentiation, EBs were 
formed in bacteriological grade Petri dishes. In brief, mESCs was enzymatically 
detached from TCP surface after 3-day culture in HepG2-CM. They were then 
gently re-suspended to small clumps and cultured in Petri dishes containing EB 
formation medium. The EB formation medium consisted of high-glucose IMDM 
(Gibco, Lifetech), 20% FBS (gold standard, PAA Laboratories), 2 mM L-
glutamine (Gibco, Lifetech), 1x penicillin-streptomycin (PAA Laboratories) and 
450 µM 1-thioglycerol (Sjgma). As the petri dishes used were of bacteriological 
grade and did not allow for cell attachment, the ESC clumps did not adhere and 
grew as an expanding cell aggregate while undergoing spontaneous 
differentiation. These cell clumps was left to grow in the EB formation medium 
for 5 days to form EBs and medium was changed every two days. 
To direct differentiation towards cardiomyocytes, 0.25 µM Cardiogenol C 
(Sigma) was added into EB formation medium as an inducing agent and this final 
medium composition was known as differentiating medium. Suspended EBs was 
then plated onto gelatin-coated 6nwell plates and cultured in differentiating 
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medium for the remaining days of differentiation. Medium was changed every 
two days.  
Ultrasound treatment was applied to cells 3 days after differentiation of mESCs 
was initiated in 2D culture (Figure 5.1). LIUS treatment on mESCs was 
conducted for 10 mins daily until Day 21. The cell-seeded plates were placed on 
top of LIUS probe (Model X Ultrasound, Rich-Mar) with an ultrasound 
transmission gel (Aquasonic 100, Parker Labs), which acts as a coupler between 
the two surfaces and prevent any presence of interfacial air bubbles that will 
affect the transmission of ultrasound.  
This whole differentiation process is briefly illustrated in different stages as 
shown in Figure 5.1 and 4 independent sets of experimental runs were conducted. 






Figure 5-1 (a) Schematic diagram of procedure of 2D conventional 
differentiation of mESCs as seen in steps 1 to 3, followed by LIUS 
treatment in step 4. (b) Timeline of addition of different media in 
different steps of differentiation and LIUS treatment. 
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5.2.3 Ultrasound treatments  
To compare the effects of ultrasound on cardiomyogenesis, mESCs were 
subjected to simulation by LIUS. Ultrasound used in this study has a working 
frequency of 1 MHz and an active area of 10 cm2.  Two parameters that were 
varied are the ultrasound generation mode, which could apply a continuous 
ultrasound wave or a pulsed ultrasound wave (Figure 5.2), and the intensity, 
which were selected to be 30 mW/cm2 and 300 mW/cm2. The generation mode 
(mode of application) determines if the ultrasound waveform would be 
transmitted continuously or with repetitive breaks (pulsed) while the intensity 
refers to the amplitude of ultrasound wave. The pulsed ultrasound waveform in 
this experiment has a pulsed repetition frequency of 1 Hz and a 20% duty cycle. 
This is illustrated in Figure 5.2, showing the contrast to the continuous 
ultrasound.    
 With these two operating parameter variations, four LIUS treatment conditions 
were obtained. They were: 
 (1) LIUS with pulsed waveform and 30 mW/cm2 intensity (30pul),  
(2) 30 mW/cm2 continuous LIUS (30cont),  
(3) LIUS with pulsed waveform and 300 mW/cm2 intensity (300pul), and  
(4) 300 mW/cm2 continuous LIUS (300cont).  
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5.2.4 Ultrasound stimulation in 3D encapsulated cultures of mESC  
As 3D cultures provide more accurate insights of in vivo cell behaviour and 
higher cell expansion fold, the impact of ultrasound on 3D cultures of mESCs 
was also studied. To enable 3D culture, mESCs were encapsulated in Ca-alginate 
hydrogel at a seeding density of 2.5 x 106 cells per ml of sterile alginate solution 
at 1.1% alginic acid sodium salt (Sigma) and 0.1% gelatin in PBS, as described in 
Section 3.2.3. 3D encapsulated ESCs were cultured under HepG2-CM for 3 days 
in 6-well plates to undergo mesodermal lineage conditioning. As the 3D cultures 
of mESCs do not require an EB formation step, unlike the 2D cultures, the 
medium was changed to the differentiating medium on Day 3.  
Eight days after changing to differentiating medium for directed cardiac 
differentiation in 3D cultures, ultrasound treatment was applied to the 3D 















Figure 5-2 Illustration of LIUS waves in continuous and pulsed (1Hz 
pulsed repetition frequency and 20% duty cycle) generation mode. 
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been demonstrated in 2D cultures. Therefore, to investigate the effects of LIUS 
on 3D cultures, only two selected LIUS conditions (30pul and 300cont) were 
used. From Day 11 to Day 21, the encapsulated cells were treated with LIUS for 
10 mins daily. The overall process is illustrated Figure 5.3 and three independent 
sets of experimental runs were conducted. 
 





Figure 5-3 (a) Schematic diagram of procedure in differentiating and 
LIUS treatment of 3D encapsulated mESCs. (b) Timeline of addition of 
different mediums in different steps of differentiation and LIUS 
treatment. 
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5.2.5 Pressure measurement of LIUS 
The pressure profiles caused by LIUS were measured and documented with a 
needle hydrophone ((HNA-0400, Onda Corporation) and digital oscilloscope 
(WaveSurfer 44MXs-B, Teledyne LeCroy). To make sure that the measured 
profiles were representative of mechanical strain and stress environments that the 
mESCs were subjected to, the hydrophone probe was positioned to a close 
proximity from the bottom well surface. The hydrophone probe was then 
immersed in degassed water. Thereafter, the LIUS transducer was placed beneath 
the whole set-up, simulating a similar set-up as the LIUS treatments on cells. 
LIUS was then transmitted according to the different conditions and the pressure 
was measured. Various points along the transducer’s output plane were measured 
to verify spatial uniformity of LIUS on the 6-well plate. 
5.2.6 Measurement of beating rates in contractile areas 
Beating colonies of the differentiating mESCs were observed with an inverted 
optical microscope (Axiovert 200M, Zeiss). The number of beatings that 
occurred in 30 secs for each contractile area was recorded and the beating rate 
was calculated. Such measurements were taken for a total of 8 – 10 contractile 
areas and 12 – 16 contractile areas for each experimental condition on Day 18 
and Day 21 respectively. 
5.2.7 Quantitative PCR 
Total RNA was isolated from cell samples with RNeasy kit (Qiagen) accordingly 
to manufacturer’s instructions. The total RNA was then quantified with UV 
spectrometer (500 Evolution, Thermo) and calculations as described in Section 
3.2.9. Using the same method in Section 3.2.9, the first strand of complementary 
DNA was synthesized from isolated RNA and used for quantitative PCR. 
Quantitative PCR was carried out with SensiFASTTM SYBR Fluorescein Kit 
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(Bioline) in iQ5 PCR Machine (Bio-rad). A typical PCR protocol involved an 
initial denaturation step of 2 mins at 95oC, followed by 40 cycles of denaturation 
at 95oC for 5 secs and annealing/extension at 60oC for 30 secs. Different genes 
were targeted by amplification with the following primers as seen in Table 5.1. 
After verifying that that all primers have similar amplification efficiencies and 
that there were no amplifications of non-targeted genes and primers-dimers,  fold 
changes in the various genes expression were calculated with 2-∆∆CT method. In 
the calculation of fold changes, the data were normalised to non-treated controls 
on Day 14, which corresponded to the start of ultrasound treatments.  
Table 5-1 List of studied genes and their respective primers in studying 
effects of LIUS on cardiomyogenesis 
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5.2.8 Flow cytometry 
To access the LIUS effects on percentage of ESCs differentiating to 
cardiomyocytes, flow cytometry was used to determine the percentage of cells 
positive for sacromeric α-actinin expression.  
 The differentiated cells were first obtained as cell pellets after enzymatic 
detachment from 6-wells and washed with PBS. They were then fixed in 4% 
paraformaldehyde (Sigma) for 15 mins and permeabilised in 0.1% Triton-X for 
another 15 mins at room temperature. Thereafter they were re-suspended in PBS 
containing 5% goat serum, 0.1% Triton-X (Ultrapure grade, USB Corporation) 
and 1% sodium azide to a concentration of 1 – 5 x 106 cells/ml. 2 µl of 
sacromeric α-actinin primary antibody (EA-53, Santa Cruz Biotechnology) was 
added to 100 µl of the re-suspended cell solution and incubated for two hours at 
4oC. After incubation, the cells were washed twice with cold PBS and re-
suspended in 100 µl of PerCP-conjugated secondary antibody (Santa Cruz 
Biotechnology, diluted 100x in 3% bovine serum albumin in PBS) for 1 hour at 
room temperature in the dark. The cells were next washed twice with cold PBS 
and stored in PBS with 2% paraformaldehyde, 3% bovine serum albumin and 1% 
sodium azide at 4oC. To analyse the stained cells, flow cytometer (FACSCalibur, 
BD Biosciences) and the results were assessed in flow cytometry analysis 
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5.2.9 Immunocytochemistry 
Expressions of cardiac proteins in differentiated cells under different LIUS 
treatments were analysed with immunocytochemistry. On Day 21, cells were 
fixed with 4% paraformaldehyde in PBS for 1 hour at room temperature. The 
fixated cell samples were then treated with 0.1% Triton-X for 45 mins to enhance 
cells’ permeability to antibodies. These samples were next incubated in primary 
antibody sacromeric α-actinin (EA-53, Santa Cruz Biotechnologies, 100x dilution 
in 0.1% sodium azide and 1% bovine serum albumin in PBS) overnight at 4oC. 
After incubation with primary antibody, they were washed thrice with PBS 
before addition of FITC-conjugated secondary antibody (Santa Cruz 
Biotechnologies, 100x dilution in 1% bovine serum albumin in PBS). Residual 
traces of antibodies were removed by three extensive washes with PBS and 
shaking for 10 mins. This whole process was then repeated for the second cardiac 
protein, cardiac Troponin I (Santa Cruz Biotechnologies, 100x dilution) and its 
TRITC-conjugated secondary antibody (Santa Cruz Biotechnologies, 100x 
dilution). After incubations with antibodies, 300 nM DAPI was added to the 
samples and incubated for 5 – 10 mins at room temperature for nuclei staining. 
The fluorescence stains were finally visualised with inverted fluorescence 
microscope (Axiovert 200M, Zeiss) and camera (AxioCam MRC, Zeiss). 
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5.2.10 Quantification of cell viability 
On Day 21, cell viability were assessed by trypan blue (Gibco, Lifetech) 
exclusion and enumerated with the usage of a hemocytometer and an optical 
microscope. Both live and dead cells were counted to obtain the viabilities of the 
different samples.  
5.2.11 Live/Dead staining  
On Day 21, cell viabilities in both 2D and 3D cultures were evaluated with 
calcein-AM (Sigma) and propidium iodide (Sigma-Aldrich). The cells or 
hydrogel beads were washed with PBS twice and incubated with 4 µM propidium 
iodide and 2 µM calcein-AM for 30 mins at room temperature in the dark. The 
samples were next washed with PBS twice. Samples were visualized and 
captured with an inverted fluorescence microscope (Axiovert 200M, Zeiss). 
5.2.12 Cell proliferation assay 
Cell proliferation of 3D encapsulated cells under different LIUS treatments and 
control conditions was also evaluated quantitatively with tetrazolium salt, WST-
8* (Cell Counting Kit 8, Dojindo), as described in Section 4.2.5. Briefly, 5 
sampled beads were washed twice with PBS and each incubated with 100 µl of 
fresh medium and 10 µl of WST-8* reagent in 37oC, 5% CO2 incubator for 2 
hours. Blank samples consisted of 100 µl fresh medium and 10 µl WST-8*. 
Thereafter, 100 µl of reacted solution from blank controls and samples were 
transferred to a new 96-well and measured for absorbance values at 450 mm in 
microplate spectrophotometer (Bio-rad).  
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5.2.13 Statistical analysis 
Statistical differences between different experimental groups were carried out 
with Microsoft Office Excel analysis tool package (Excel 2007, Microsoft). F-test 
was first used to determine for equal variances in the different data sets. Upon 
determining that there were unequal variances in some experimental groups, 
student t-test with unequal variances were used. Data in beating rates, 
quantitative PCR, flow cytometry, viability test, and cell metabolism assay were 
analysed with the student t-test with unequal variances for differences of 95% 
significance level. Error bars on the charts were representative of the standard 
deviations. The sample populations (N) are indicated in the legends of the 
respective figures and represent the number of independent experimental runs, 
unless as indicated in the legend. The error bars represent the standard deviation 
of different experimental groups and were calculated by the Microsoft Office 
Excel.  
- 153 - 
 
5.3 Results 
5.3.1 Pressure levels exerted on cells under different intensities of 
LIUS 
In this chapter, there were different conditions used in LIUS treatments on the 
cells, as described in Section 5.2.3. The combinations of intensity and ultrasound 
generation mode resulted in four LIUS treatment conditions as seen in Table 5.2.   
Table 5-2 Operating conditions and naming convention of LIUS treatments 
 Pulsed ultrasound Continuous ultrasound 
30 mW/cm2 30pul 30cont 
300 mW/cm2 300pul 300cont 
 
30 mW/cm2 is commonly found in chondrogenesis and osteogenesis of stem cells 
and progenitors for cartilage and bone regeneration. Meanwhile, 
cardiomyogenesis under ultrasound stimulation with an intensity of a magnitude 
higher such as 300 mW/cm2 was also investigated. 300 mW/cm2 is chosen as it is 
still within the Federal and Drug Administration limit of 430 mW/cm2 [221].  
As seen in Figure 5.4, hydrophone measurements showed that 30 and 300 
mW/cm2 LIUS imposed pressure waves of amplitudes 20.1 ± 1.5 and 66.5 ± 1.5 
kPa on the cells respectively. Ultrasound intensity is directly proportional to the 
square of pressure amplitude, thus this 3-fold increase in pressure amplitude 
corresponded with the 10-fold intensity increase. After the pressure profiles 
which 30 and 300 mW/cm2 LIUS would exert on the cells (Figure 5.4) were 
verified, the LIUS’s effects on differentiating ESCs towards cardiomyocytes 
were then studied. 
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5.3.2 Evaluation of contractile areas in 2D cultures under LIUS 
treatments 
Beating colonies were spotted in 2D cultures after about 18 days. The contractile 
areas of differentiated mESCs on 2D cultures were evaluated by counting their 
beating rates on Day 18 and 21. Figure 5.5 shows the average beating rates of 
contractile areas that were obtained from mESCs under different LIUS 
treatments. On Day 18, cells under 300cont LIUS treatments gave a beating rate 
of 41 beats per minute, which was significantly higher than the controls and other 
treated samples. By Day 21, LIUS treatments managed to give rise to higher 
beating rates in most of the treated samples when compared to the untreated 
samples. Samples that were treated with LIUS, with the exception of 30cont 
Figure 5-4 Pressure profiles induced on cells by LIUS treatments of 
intensities at 30 mW/cm2 and 300 mW/cm2. 
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LIUS, produced higher beating rates than controls. These showed that LIUS 
could generally enhance ESC-differentiated cardiomyocytes’ contractile 
properties. 
 
5.3.3 Cardiac gene expression of mESCs in 2D cultures under different 
LIUS treatments 
Cardiac differentiation was evaluated by comparing cardiac gene expression of 
cells which were differentiating in 2D cultures and subjected to no LIUS 
(control) or different LIUS conditions. Their gene expressions were studied after 
3, 7 and 10 days of treatment (Day 14, 18 and 21 of culture respectively). Each 
experiment group was normalised to the genes levels expressed in controls on 
Day 14. On Day 14, after the cells were subjected to only three days of LIUS, 
they showed a significant increase of Brachyury T regulation from the controls, 
Figure 5-5  Beating counts of contractile areas in 1 minute for different 
LIUS-treated samples and controls on Day 18 and 21. Scale bar 
represents significant difference of indicated sample from its respective 
control. * represents significant difference between the indicated sample 
and its intensity counterpart (e.g. 30 mW/cm2 pulsed and 300 mW/cm2 
pulsed LIUS). ^ represents significant difference between the indicated 
sample and its pulsing counterpart (e.g. 30 mW/cm2 pulsed and 30 
mW/cm2 continuous LIUS). p < 0.05, n = 8 – 12 from 3 independent runs  
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regardless of the LIUS conditions that they were subjected to (Figure 5.6 (a)). 
This indicated that LIUS produced cues for directed ESCs towards mesodermal 
commitment, thereby increasing the probabilities for ESCs’ cardiomyogenesis. 
Meanwhile, on Day 14, LIUS with higher intensity (300 mW/cm2) also caused 
higher gene expressions of early cardiac progenitor Nkx2.5 than its counterparts 
with 30 mW/cm2, regardless of the generation mode (Figure 5.6 (b)). 
When expressions of late cardiac markers (i.e. α-MHC, β-MHC and cTNT) were 
compared, as shown in Figure 5.7, there were gene upregulations that were more 
pronounced at 30pul and 300cont LIUS than at 30cont and 300pul LIUS. At Day 
18, 300cont LIUS produced significant higher upregulation of cardiac myosin 
heavy chains (both α-MHC and β-MHC) than the controls. Meanwhile, 30pul 
LIUS did not produce any significant increase in expressions of cardiac genes on 
Day 18 and actually caused a delayed upregulation. However by Day 21, 
expressions of cTNT and α-MHC increased in 30pul samples significantly, 
giving higher expression levels than the controls. This demonstrated a similar 
enhancement in 30pul LIUS on cardiomyogenesis as that of 300pul LIUS, though 
the observed effects were delayed. 
These results of cardiac gene expressions corresponded to the higher beating rates 
induced by LIUS treatments, where 300cont LIUS gave rise to higher beating 
rates since Day 18 and 30pul also produced such effect on Day 21. As such, it 
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Figure 5-6 Fold changes in expression of (a) mesodermal marker, 
Brachyury T, and (b) early cardiac progenitor, Nkx-2.5 on Day 14, 18 
and 21 of differentiation process for mESCs cultured on 2D plates. Bar 
represents significant difference of indicated sample from its respective 
non-treated control. * represents significant difference between the 
indicated sample and its intensity counterpart. ^ represents significant 
difference between the indicated sample and its pulsing counterpart. p 
< 0.05, N = 4. 
(b) 
(a) 
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Figure 5-7 Fold changes in expression of late cardiac markers (a) α-MHC,  
(b) β-MHC and (c) cTnT on Day 14, 18 and 21 for mESCs cultured on 2D 
plates. Bar represents significant difference of indicated sample from its 
respective non-treated control. * represents significant difference between 
the indicated sample and its intensity counterpart. ^ represents 
significant difference between the indicated sample and its pulsing 
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5.3.4 Percentage of sacromeric α-actinin cells in 2D mESC cultured 
differentiated under ultrasound conditions 
As observed from the gene expression data, LIUS upregulated cardiomyocyte 
differentiation of mESCs in 2D cultures. The percentages of differentiated 
mESCS under different LIUS treatments which were positive for sacromeric α-
actinin (ATN) were also determined by flow cytometry. ATN binds actin 
filament to dense striations to enable contractile motion in cardiomyocytes. 
Figure 5.8 shows the summary of ATN-positive cell percentages under different 
LIUS conditions and a representative flow cytometry histogram from each LIUS 
condition. All LIUS treatments produced differentiated cell populations with 60 – 
70% ATN-positive cells, while the control gave rise to only 34.3%.  This showed 
that LIUS had significantly improved cardiomyocyte differentiation regardless of 
the conditions used. Among the different LIUS conditions, 30pul and 300cont 
LIUS gave rise to the highest percentage of ATN-positive cells (around 70%) 
while the other two conditions (30cont and 300pul LIUS) only produced around 
60%. This correlated to the gene expression study and further showed the optimal 
LIUS conditions for cardiomyogenesis of mESCs in the 2D culture setup were 30 
mW/cm2 pulsed and 300 mW/cm2 continuous US.  
  





(b) Isotype control (c) Control (d) 30pul 
(e) 30cont (f) 300pul (g) 300cont 
Figure 5-8 Percentage of ATN-positive cells under different LIUS conditions 
for 2D cultures. (a) Comparison of ATN-positive cells under different 
LIUS conditions. Bar represents significant difference of indicated 
sample from the non-treated control. * represents significant 
difference between the indicated sample and its intensity counterpart. 
^ represents significant difference between the indicated sample and 
its pulsing counterpart. p < 0.05, N = 3. Flow cytometry histograms of 
(b) isotype control (a control showing unspecified staining), and of 
ATN-positive cells under (c) no LIUS treatment (control), (d) 30pul, 
(e) 30cont, (f) 300pul, and (g) 300cont LIUS treatments.  
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5.3.5 LIUS’s effects on development of structural cardiac proteins in 
differentiated cells in 2D cultures 
To ensure that LIUS was not detrimental to development of structural and cardiac 
proteins on cell surface, the protein expressions of ATN and cardiac troponin I 
(cTNI) on Day 21 was evaluated via immunostaining on Day 21 (Figure 5.9). 
Based on cardiac gene expressions and percentrage of cells positive for 
sacromeric α-actinin, it was inferred that 30pul and 300cont LIUS gave rise to the 
highest cardiomyocyte yields. Thus only protein expressions of 30pul and 
300cont samples were compared with that in the non-LIUS treated controls. 
ATN and cTNI protein expressions are represented by the green and red 
fluorescence signals respectively in Figure 5.9. Comparing to the nuclei layout of 
their corresponding nuclei micrographs, these two proteins showed intense, 
extensive and fairly uniform expressions in 30pul and 300cont samples. Thus 
LIUS did not pose any detrimental effects to development of cardiac proteins. 







Figure 5-9 Fluorescence micrographs of immunocytochemistry with 
cardiac markers, ATN (FITC–green) and cTNI (TRITC–red) with their 
respective nuclei staining (DAPI–blue) after 21 days of 2D culture in (a) 
non-LIUS treated controls, (b) 30pul samples, (c) 300cont samples, and (d) 
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5.3.6 Spontaneous differentiation towards endodermal and 
ectodermal lineages under LIUS treatments in 2D cultures 
Besides cardiac differentiation of ESCs, spontaneous differentiation towards 
endodermal and ectodermal lineages was monitored with gene expression levels 
of alpha-fetoprotein (AFP) and Nestin. In general, there was no significant 
difference in Nestin expression among the controls and LIUS samples (Figure 
5.10 (b)) during the entire culture period, except for the lower expression levels at 
30cont on Day 21. In contrast, AFP expressions gave a different observation 
(Figure 5.10 (a)). Cells under all LIUS treatments produced lower expression 
levels of AFP than the controls. For instance, the controls gave upregulation of 17 
and 31 folds at Day 18 and 21 respectively while that in LIUS-treated samples 
were only 1.5 – 6 and 8 – 20 folds. 




Figure 5-10 Fold changes in expression of (a) endodermal marker, AFP and 
(b) ectodermal marker, Nestin on Day 14, 18 and 21 of mESCs in 2D 
culture. Bar represents significant difference of indicated sample from its 
respective control. * represents significant difference between the indicated 
sample and its intensity counterpart. ^ represents significant difference 
between the indicated sample and its pulsing counterpart. p < 0.05, N = 4. 
(a) 
(b) 
- 165 - 
 
5.3.7 Evaluation of cell viabilities 
The viability of differentiated mESCs in standard 2D flasks was poor at Day 21 
(Figure 5.11 (a – c)). Viability ranged 48 – 52% in non-LIUS treated controls 
treated samples (Table 5.3). The similarities of viabilities in controls and treated 
samples indicated that there cell death due to stress from LIUS treatments might 
be insignificant. Substantial cell death observed in the standard 2D culture could 
be a result of the apoptotic cores during EB formation. During the EB formation, 
which was prior to the replating step and ultrasound treatment, the cell density 
and size of suspended EBs might have increased till the extent that the cells faced 
severe nutrient transport limitations, resulting in apoptotic cores. mESCs were 
then encapsulated in alginate hydrogel to provide a 3D environment in hope to 
improve viabilities while enhancing cellular interactions. From the viability 
staining results, the overall viability of encapsulated mESCs in 3D cultures on 
Day 21 were significantly better (Figure 5.11 (d – f)) than those observed in 
standard 2D cultures.  
Table 5-3 Viabilities of non-LIUS treated controls and LIUS-treated samples 
at Day 21 for 2D culture, as quantified by cell enumeration with Trypan blue 
and hemocytometer. Lack of significant differences as assessed by student t-
test of unequal variance. p < 0.05, N = 4.  
Viability (%) 
Control 30pul 30cont 300pul 300cont 
48.8 ± 4.9 48.3 ± 6.8 50.9 ± 7.2 52.0 ± 4.4 50.9 ± 7.0 
- No significant difference 
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Furthermore, cell proliferation assay of encapsulated mESCs under 30pul and 
300cont LIUS treatments showed no significant differences in the metabolic 
activities from the controls throughout the entire stimulation period (Figure 5.12). 
This indicated that these studied LIUS conditions would not cause significant 
deleterious effects on cell proliferation and viabilities in 3D cultures. 





























Figure 5-11 Live/dead fluorescence images at of differentiated cells in (a – 
c) conventional 2D cultures and (d – f) 3D encapsulated aggregates on day 
21, where green and red fluorescence represent live and dead cells 
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5.3.8 Cardiomyogenesis and spontaneous differentiation of 3D-
encapsulated ESCs under 30pul and 300cont LIUS treatments 
Since 30pul and 300cont LIUS were found to produce the highest 
cardiomyocytes yield (Figure 5.7 and Figure 5.8), these two conditions were used 
to determine if LIUS would have any significant impact in the 3D platform as it 
had in the 2D platform. Nkx 2.5 and cTNT gene expressions did not show any 
significant difference between the controls and LIUS-treated samples of 
encapsulated ESCs (results not shown). However, on Day 14, 300cont LIUS 
induced a higher upregulation of Brachyury T than the controls and 30pul LIUS 
samples (Figure 5.13 (a)). At Day 21 (Figure 5.13), there were increased 
expressions of Brachyury T, α-MHC and β-MHC in 300cont LIUS-treated cells 
while 30pul LIUS samples showed no significant difference from the control.  
Brachyrury T is a marker for mesodermal lineage commitment and is usually a 
transient marker. However, it showed a second round of upregulation on Day 21. 
This correspond to the decrease in pluripotent genes’ expressions (Nanog and 
Figure 5-12 Cell proliferation of 3D encapsulated ESCs under control, 
30pul and 300cont LIUS conditions. * represents significant difference 
between the indicated sample and its previous time point. Bar represents 
significant differences between LIUS conditions. However, the lack of 
bar indicates there is no cell proliferation differences among the samples 
at the respective time points.  p < 0.01, N = 10 from 2 independent runs. 
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Oct-4 in Figure 5.14). The second round of Brachyury T’s upregulation could be 





Figure 5-13 Fold changes 
in cardiac gene 
expressions of (a) 
Brachyury T, (b) α-MHC 
and (c) β-MHC in 3D 
encapsulated cell 
aggregates on Day 14, 18 
and 21 of differentiation 
process. Bar represents 
significant difference of 
indicated sample from its 
respective control. * 
represents significant 
difference between the 
indicated sample and its 
previous time point. p < 
0.05, N = 3 
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Similar observations in the AFP expression were made in both conventional 
culture and 3D platform. All LIUS-treated samples in 3D cultures also had lower 
AFP expressions than the controls (Figure 5.15 (a)). This implied that LIUS also 
reduced the spontaneous differentiation of mESCs towards endodermal lineage in 
the 3D platform. Meanwhile, there was no significant difference in Nestin 
expression among the LIUS-treated samples and the controls (Figure 5.15 (b)). 
So far, our results on LIUS effects on mESC differentiation in 3D cultures were 
consistent with those observed in 2D culture. 
(a) 
(b) 
Figure 5-14 Fold changes in pluripotent gene expressions of (a) Nanog, and 
(b) Oct-4 in 3D encapsulated cell aggregates on Day 14, 18 and 21. Bar 
represents significant difference of indicated sample from its respective 
control. * represents significant difference between the indicated sample 
and its previous time point. p < 0.05, N = 3 






Figure 5-15 Fold changes in cardiac gene expressions of (a) endodermal 
marker, AFP and (b) ectodermal marker, Nestin in 3D encapsulated cell 
aggregates on Day 14, 18 and 21 of differentiation process. Bar represents 
significant difference of indicated sample from its respective control. * 
represents significant difference between the indicated sample and its 
previous time point. p < 0.05, N = 3 
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5.4 Discussion 
Cardiomyocyte differentiation and maturation from cell sources like neonatal 
cardiomyocytes, MSCs and ESCs has been shown to improve under mechanical 
stimulation [8-10]. This chapter demonstrates the feasibility of using LIUS as a 
novel mechanical stimulation in enhancing cardiomyogenesis of mESCs. The 
higher percentage of cardiomyocytes obtained and the higher beating rate showed 
that LIUS could generally increase the extent of mESC differentiation towards 
cardiomyocytes. One possible explanation is that LIUS generated motions and 
forces in the culture medium and elicited biophysical effects similar to those from 
mechanical stimulus on mESCs, resulting in mechanotransduction effects. 
Although LIUS is shown to enhance cardiomyogenesis generally, there are 
different parameters in operating ultrasound stimulation, e.g. intensity, which will 
affect its efficacy. Different LIUS conditions were used to treat the cells in this 
chapter and different parameters gave rise to different extent of cardiomyogenesis 
enhancement. For instance a longer period of treatment and culture was required 
for 30 mW/cm2 pulsed LIUS than 300 mW/cm2 continuous LIUS. This might be 
attributed to the higher pressure induced by 300 mW/cm2 continuous LIUS, 
which might then create a higher mechanical stress and strong 
mechanotransdiction effects on the mESCs. Such observations indicated the need 
for optimisation of LIUS for different cell types and cardiogenic conditions. 
A distinct effect of LIUS stimulation on mESC differentiation in this study was 
the reduced spontaneous differentiation towards endodermal lineages. When 
compared to endodermal commitment, both mESC and hESC commitment 
towards mesodermal lineages were favoured on stiffer substrates [222, 223]. 
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Zoldan et al. then suggested substrates of different stiffness would exert different 
levels of counteracting forces on the cells and affect their cellular fate [223]. 
Hence, a stiffer substrate would impose higher forces on the cells, implying that 
mesodermal commitment will prefer higher stress environment than endodermal 
commitment. Similarly, mesodermal commitment in an in vivo embryonic 
development experiences tensional and intercellular forces for migration towards 
midline of primitive streak and formation of heart tube [224]. These studies 
substantiate the hypothesis that LIUS stimulation provides mechanical stress as 
forces that drove ESC commitment away from endodermal lineages and direct it 
towards the mesoderm lineage in a cardiogenic environment. This could be a 
useful strategy in minimizing spontaneous differentiation of ESCs towards 
undesired lineages and increasing the purity and yield of cardiomyocytes from 
pluripotent stem cells. 
Using a 3D substrate for cell culture would make it easier for handling in a 
dynamic bioreactor, thus enabling an efficient scalable bioprocess. Culturing cells 
in a 3D environment could achieve higher cell densities and provide a better in 
vivo mimicry, providing advantages over the conventional 2D cultures. For 
instance, cardiomyogenesis in 3D environment produced cardiomyocytes that 
bore greater resemblance to those in the myocardium [4, 5]. Moreover, hydrogel 
encapsulation can enable aggregate size control during proliferation and also 
support long-term culture, which will be beneficial to cardiomyogenesis [124-
126].  In this study, encapsulation of ESCs in Ca-alginate hydrogel has allowed 
cells to maintain a higher viability than the conventional differentiation method 
as it eliminates the need for EB formation which can cause a higher apoptotic 
presence. Hydrogels also have a protective function from any hostile extrinsic 
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factors [225-227]. Despite the benefits of hydrogel encapsulation on cell 
viability, LIUS’s induction of cardiomyogenesis was not as pronounced in 3D 
environment as in conventional 2D culture. In 2D culture, 300 mW/cm2 
continuous LIUS could increase cardiac gene expressions as early as Day 18 but 
such improvements were only observed on Day 21 in the encapsulated cells. 
Furthermore, upregulated cardiac gene expressions caused by 30 mW/cm2 pulsed 
LIUS which were observed in the 2D cultures, were also absent in the 
encapsulated cells during the experimental period. Nicodemus and Bryant have 
demonstrated that culture of chondrocytes in hydrogel has built up an endogenous 
matrix around the cells, which might protect them from sensing the mechanical 
stimuli [228]. Therefore, one possible reason for the reduced effect of LIUS in 
3D environment is that the hydrogel has provided a protective buffer against the 
mechanical loads of LIUS treatment, thus reducing the effects of 
mechanotransduction and mechanical stimuli. 
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5.5 Conclusion 
Obtaining cardiomyocytes from cell sources such as pluripotent cells can be 
enhanced by incorporating biophysical simulations in bioprocess, such as 
mechanical stimuli. Though LIUS has been studied for bone and cartilage 
regeneration, its effects had yet to be investigated for cardiomyogenesis. This 
chapter showed the feasibility and benefits of LIUS utility in driving cardiac 
differentiation from mESCs. Specific treatments of LIUS could increase cardiac 
gene expressions and beating rates of contractile areas. Besides conventional 2D 
culture, improved cardiomyogenesis was also demonstrated in 3D encapsulated 
mESCs. 3D cultures hold a promising future as a platform for large scale 
production for obtaining cardiomyocytes with clinical relevant numbers. This 
chapter demonstrates the feasibility of using LIUS for cardiomyogenesis of 
mESCs. Once similar studies are also established using human-sourced cells, 
LIUS stimulation and 3D cultures can create a synergistic platform to obtain 
cardiomyocytes with translatable quantities and contractile properties for clinical 
therapies. 
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Cardiovascular diseases are major global mortality causes, especially in 
developed countries. To date, there is no clinical therapy which can fully 
regenerate the infarcted myocardium functionality except for heart 
transplantation. Strategies of ex vivo cardiomyocyte production from stem cells 
offer promising opportunities for cell transplantation to regenerate the cardiac 
tissue. However, one should consider the issues and challenges in such strategies, 
such as the ability to achieve clinically relevant cell numbers efficiently and 
reproducibly. In this thesis, encapsulated mESCs, an established and pluripotent 
cell type, was used as a model to investigate the effects of various cell culture / 
bioprocess considerations that will help to advance the development of 3D stem 
cell cultures. These factors include the effects of different cell culture platforms, 
pH environments and mechanical stimulation, in form of US, on obtaining 
cardiomyocytes for clinical therapies. 
For large scale cell culture and reproducibility of cellular products, bioreactors 
can be developed as a highly feasible platform. Different culture platforms which 
adopt different mixing and feeding strategies, result in different hydrodynamic 
flow profiles and thus nutrients’ availability to cells will also be affected. A novel 
bioreactor, which incorporated rotary mixing and perfusion, was used in mESC 
cardiomyogenesis. The dynamic flow environment provided by rotary mixing is 
beneficial to cell viability and produces better cell expansion, including that in 
cardiomyocytes, than a static environment. Moreover, rotary mixing gives rise to 
low shear stress environment which are more preferentially for cardiomyogenesis 
and will also eliminate any risk in cell death by high shear stress. Perfusion is a 
common feeding strategy to provide a continuous exchange of nutrients and 
metabolites, so as to maintain a consistent environment for cell culture. With a 
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continuous supply of cardiomyogenic factors and removal of inhibitory factors in 
this novel bioreactor, cellular fate of ESCs is better controlled and differentiation 
towards cardiomyocytes is enhanced. 
Consistent environment, as provided by perfusion, was shown to enhance 
cardiomyogenesis of encapsulated mESCs. However, consistency of culture 
parameters is usually difficult to achieve in conventional TCP and culture 
platforms, especially when cell numbers are high. A common fluctuating culture 
parameter is the environmental pH. Due to accumulation of respiratory 
metabolites, pH tend to decrease and can affect cardiomyogenesis. As from our 
findings, differentiating mESCs at pH 6.8 will cause a lower yield of 
cardiomyocytes and higher residual pluripotency than at pH 7.1 and 7.4. 
Furthermore, cell proliferation and viabilities were compromised when pH 
decreased to pH 6.8. Though an environment of pH 6.8 is not drastically different 
from normal culture environments, the impact on cardiomyogenesis was 
significant. This is an indication of pluripotent cells’ sensitivity to pH 
environments during cardiac differentiation. Thus to ensure reproducibility of 
cellular products from different culture batches and to increase cardiomyocyte 
yield, one should consider the importance of pH environment and determine an 
optimal environment. 
Mechanical stimulation is also extensively studied for its effects on 
cardiomyocyte differentiation and maturation. From its impact on bone and 
cartilage regeneration, LIUS is a possible candidate in producing mechanical cues 
to enhance cardiomyogenesis from cell sources. LIUS’s complementary effects 
on cardiomyocyte differentiation of mESCs was demonstrated in both 
conventional 2D and 3D cultures. In addition, LIUS reduced the likelihood for 
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mESC spontaneous differentiation towards endodermal lineages significantly. 
This can be used to increase selectivity of cardiomyocytes from mESC 
differentiated cell products. A distinct advantage of using LIUS is that 
incorporation of LIUS stimulation into a culture platform, such as bioreactors, 
which requires only a simple installation of the ultrasound transducer probes. 
This makes the application of LIUS probes readily adaptable to a wider range of 
culture vessel and bioreactor designs. Thus LIUS was shown to be a novel form 
of mechanical stimulus to complement a 3D bioprocess in obtaining 
cardiomyocytes for clinical therapies. 
In developing a platform to produce cardiomyocytes for clinical therapies, it is 
important to consider bioprocess design parameters in a cell culture platform. 
One such parameter is the bioreactor design and its hydrodynamic profile and 
feeding strategy. A novel rotary perfused bioreactor could successfully enhance 
cardiomyogenesis as compared to that in conventional static cultures. Another 
parameter which was found to be important was the ability to control and 
maintain physiological environment, such as extracellular pH.  Cardiomyogenesis 
is sensitive to slight pH changes and thus uncontrolled environment, which is 
vulnerable to fluctuations, will make it difficult to ensure reproducibility of 
cellular products. Last but not least, LIUS was also used as a novel form of 
mechanical stimulation for cardiomyogenesis of mESCs. It was demonstrated 
that LIUS was not only feasible but also improved cardiomyocyte yield, showing 
the ability to use LIUS as a strategy to obtain cardiomyocytes for clinical 
therapies.  
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6.1 Recommendation for future works 
6.1.1 Translation into clinical practices 
Findings in this thesis were primarily based on the mESC model. For clinical 
translation, studies on human pluripotent stem cells should be conducted in the 
future roadmap. Bioprocess parameters investigated in this thesis, such as the 
well-mixed and perfused environment in the novel bioreactor and pH sensitivity, 
would have similar effects across species. For instance there were studies using 
mESC as a model for human pluripotent stem cells in large-scale bioreactor 
platforms. These studies showed the benefits of 3D cultures (on microcarriers and 
in encapsulation) and bioreactor cultures on the cell expansion and 
cardiomyogenesis of mESCs [115, 126, 229, 230]. Further development then 
demonstrated similar findings with human pluripotent stem cells in microcarriers 
and bioreactor cultures [119, 126, 230-232]. In similar context, the results 
presented in this thesis could help to evaluate the feasibility of novel bioprocess 
conditions for the utility of human pluripotent stem cells. However, specific 
operating conditions such as flow rate or optimal culture pH may differ when 
culturing human pluripotent stem cell culture and should be optimised 
independently. Thus more elaborated studies, including assessment of functional 
properties of the derived cardiomyocytes, should be carried out in the future. 
In utilising pluripotent stem cells for producing specific differentiated cells, one 
major concern is the purity. Differentiated cell populations originating from 
pluripotent cell sources usually comprise residual pluripotent cells and cells of 
undesired lineages. The residual pluripotent cells can spontaneously differentiate 
into other undesired cell types and it takes only a few hundred pluripotent stem 
cells in transplantation to form teratoma [3]. Therefore, in the application of 
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ESC-derived products into clinical practice, purification methods used to isolate 
the desired differentiated cell population is a necessity, and in vitro and in vivo 
efficacy and safety must be tested to the most stringent standards set by 
regulatory authorities. In this thesis, it was observed that there was a substantial 
amount of pluripotent gene and protein expressions and endodermal gene 
expression after 21 days of differentiation. Since purity and safety issues have yet 
been addressed in this thesis, further works are required to address these issues.  
To increase cardiomyocyte purity, cardiogenic cells are to be separated from 
other differentiated cells and residual pluripotent cells prior to transplantation. 
Purification of cardiomyocytes has been demonstrated by separation on a Percoll 
density gradient [233] and genetic selection in modified ESC line [234] to a 
purity level of 71 – 95% and 91.5% respectively. To obtain higher purity levels 
while avoiding the need for genetic modifications, fluorescence cell-sorting of 
non-genetic markers such as mitochondrial content [235] or cell surface epitope 
[236] could be used. Purity greater than 99% have been obtained for such 
methods. However, fluorescence cell sorting would require single cell suspension 
and the preparation of a viable cell suspension usually resulted in great loss of 
cardiomyocytes [236], making it unsuitable for producing cells with clinically 
relevant numbers. On top of purification, it should also be determined if the 
purified products is safe for transplantation with teratoma assays performed in 
animal models.  
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6.1.2 Ultrasound stimulation  
LIUS is found to enhance cardiomyogenesis of mESCs in a cardiogenic 
environment. One benefit of using LIUS is its versatility to be incorporated into 
different bioreactor designs. It was also demonstrated that the novel rotary 
perfused bioreactor can help to increase cardiomyocyte yield from mESCs. 
Therefore, incorporating LIUS into this novel bioreactor may have synergistic 
effects, compounding their benefits in producing cardiomyocytes for clinical 
therapies. One suggestion for future work is to investigate if there is any 
enhancement in cardiomyocyte differentiation in such rotary perfused bioreactor 
with LIUS stimulation. 
Though LIUS was shown to enhance cardiomyogenesis in both 2D and 3D 
cultures, its ability to improve cardiomyocyte differentiation was attenuated by 
the protective barrier of 3D encapsulation.  Hence more detailed studies will be 
needed to determine optimal LIUS operating conditions for cardiomyogenesis of 
these encapsulated cells. For instance, higher LIUS intensity can be applied to 
study if there is an earlier onset or higher levels of cardiac gene expression. 
Moreover, LIUS treatment comprises of various operating parameters, such as 
ultrasound frequency, intensity, duty cycle and treatment duration. So far 
ultrasound was shown to be feasible to act as a mechanical stimulation to enhance 
cardiomyogenesis, and its impact from varying intensity and duty cycle was also 
demonstrated. However, there are other operating parameters which will also 
have impact of cardiomyogenesis and further studies are required. Thus, further 
investigation can be conducted to determine the effects of different parameters on 
cardiomyogenesis.  
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Ultrasound is a novel form of mechanical stimulation in mESC cardiomyogenesis 
and has never been utilised before for this purpose. Hence its effects on specific 
cellular behaviours are still unknown and will require more extensive studies. For 
instance AT1, a mechanoreceptor commonly found in cardiomyocytes, was 
observed to be upregulated in LIUS-treated osteoblasts. This receptor may play 
an important role in improving cardiac regeneration under LIUS treatment. 
Therefore, further studies in mechanotransduction can be conducted to enable a 
better understanding of the molecular mechanism triggered by ultrasound 
stimulation. Upon studying the molecular mechanism, such understanding can be 
used as a reference for elucidating ultrasound effects on cardiomyogenesis of 
human pluripotent cells. 
The above suggestions are some future studies which arise from the reported 
findings in this thesis. However, a 3D bioprocess to produce cardiomyocytes of 
clinically relevant numbers and functionalities requires many design 
considerations. Therefore, the list of parameters for investigation and 
optimisation is not exhaustive. Tissue engineering and regenerative therapies are 
rapidly advancing fields in the biomedical industry and calls for the 
amalgamation of different expertise to address the multi-faceted challenges 
required in translating research outcomes into the clinic.   
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